10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018.

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from________ to_________.

Commission File Number: 001-38298

Zomedica Pharmaceuticals Corp.

(Exact name of registrant as specified in its charter)

Alberta, Canada	N/A
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

100 Phoenix Drive, Suite 190 Ann Arbor, Michigan	48108
(Address of principal executive offices)	(Zip code)

(734) 369-2555

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X ] No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[  ]		Accelerated filer	[  ]
Non-accelerated filer	[  ]	(Do not check if a smaller reporting company)	Smaller reporting company	[X]
			Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

As of August 9, 2018, 94,511,209 shares of the registrant’s common shares, without par value, were issued and outstanding.

Zomedica Pharmaceuticals Corporation

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

JUNE 30, 2018

TABLE OF CONTENTS

	Page
PART I
FINANCIAL INFORMATION
1. Condensed Financial Statements	3
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
3. Quantitative and Qualitative Disclosures about Market Risk	30
4. Controls and Procedures	30
PART II
OTHER INFORMATION
1. Legal Proceedings	31
1A. Risk Factors	31
2. Unregistered Sales of Equity Securities and Use of Proceeds	37
3. Defaults Upon Senior Securities	37
4. Mine Safety Disclosures	37
5. Other Information	37
6. Exhibits	37

2 

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

Zomedica Pharmaceuticals Corp.

Condensed unaudited interim consolidated balance sheets

As at June 30, 2018 and December 31, 2017

(Stated in United States dollars)

			June 30,			December 31,
	Note		2018			2017
Assets
Current assets:
Cash and cash equivalents			$	4,279,163		$	3,448,147
Prepaid expenses and deposits		5		1,135,234			786,273
Trade and other receivable				49,627			28,272
				5,464,024			4,262,692
Prepaid expenses and deposits		5		495,481			566,832
Property and equipment		6		444,692			371,157
Intangible assets		7		13,762			15,141
			$	6,417,959		$	5,215,822
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and accrued liabilities			$	1,683,802		$	828,737
				1,683,802			828,737
Shareholders' equity:
Capital stock
Authorized
Unlimited common shares without par value
Issued and outstanding
94,511,209 common shares (2017 - 90,225,869)		9		25,258,124			18,244,659
Additional paid-in capital		10		1,417,860			1,768,526
Accumulated deficit				(21,941,827	)		(15,626,100	)
				4,734,157			4,387,085
			$	6,417,959		$	5,215,822

The accompanying notes are an integral part of these condensed unaudited interim consolidated financial statements.

3 

Zomedica Pharmaceuticals Corp.

Condensed unaudited interim consolidated statements of operations and comprehensive loss

For the three and six months ended June 30, 2018 and 2017

(Stated in United States dollars)

			Three months ended June 30,						Six months ended June 30,
	Note		2018			2017			2018			2017
Expenses:
Research and development		14	$	2,534,620		$	504,235		$	3,134,961		$	1,120,684
General and administrative		14		1,248,490			748,610			2,408,662			1,575,635
Professional fees		14		336,455			314,658			708,402			696,194
Amortization		7		693			700			1,379			1,399
Depreciation		6		27,459			22,782			64,158			43,090
Loss from operations				4,147,717			1,590,985			6,317,562			3,437,002
Gain on settlement of liabilities				-			-			-			(5,000	)
Foreign exchange gain				(3,319	)		(2,615	)		(1,835	)		(10,896	)
Loss before income taxes				4,144,398			1,588,370			6,315,727			3,421,106
Income tax expense				-			-			-			-
Net loss and comprehensive loss			$	4,144,398		$	1,588,370		$	6,315,727		$	3,421,106
Weighted average number of common shares - basic and diluted				92,527,470			87,077,768			91,527,862			85,622,780
Loss per share - basic and diluted			$	(0.04	)	$	(0.02	)	$	(0.07	)	$	(0.04	)

Nature of operations and going concern (Note 1)

Commitments and contingencies (Note 11)

The accompanying notes are an integral part of these condensed unaudited interim consolidated financial statements.

4 

Zomedica Pharmaceuticals Corp.

Condensed unaudited interim consolidated statements of shareholders’ equity

For the three and six months ended June 30, 2018 and 2017

(Stated in United States dollars)

	Note		Number of capital stock		Capital stock		Additional paid-in capital			Accumulated deficit			Total
Balance at December 31, 2016				83,964,569	$	10,189,973	$	1,205,456		$	(7,561,028	)	$	3,834,401
Stock issuance for services		9		43,613		45,000		-			-			45,000
Stock issuance for financing, net of cost		9		2,902,682		3,215,876		-			-			3,215,876
Stock-based compensation		10		-		-		161,590			-			161,590
Stock issued due to exercise of options		9		497,060		53,707		(14,163	)		-			39,544
Net loss for the period				-		-		-			(3,421,106	)		(3,421,106	)
Balance at June 30, 2017				87,407,924	$	13,504,556	$	1,352,883		$	(10,982,134	)	$	3,875,305
Balance at December 31, 2017				90,225,869	$	18,244,659	$	1,768,526		$	(15,626,100	)	$	4,387,085
Stock issuance for services		9		641,717		1,238,513		-			-			1,238,513
Stock issuance for financing, net of cost		9		1,861,627		3,978,690		-			-			3,978,690
Stock-based compensation				-		-		7,288			-			7,288
Stock issued due to exercise of options		10		1,781,996		1,796,262		(357,954	)		-			1,438,308
Net loss for the period				-		-		-			(6,315,727	)		(6,315,727	)
Balance at June 30, 2018				94,511,209	$	25,258,124	$	1,417,860		$	(21,941,827	)	$	4,734,157

The accompanying notes are an integral part of these condensed unaudited interim consolidated financial statements.

5 

Zomedica Pharmaceuticals Corp.

Condensed unaudited interim consolidated statements of cash flows

For the three and six months ended June 30, 2018 and 2017

(Stated in United States dollars)

			Three months ended June 30,						Six months ended June 30,
	Note		2018			2017			2018			2017
Cash flows used in operating activities:
Net loss for the period			$	(4,144,398	)	$	(1,588,370	)	$	(6,315,727	)	$	(3,421,106	)
Adjustments for
Depreciation		6		27,459			22,782			64,158			43,090
Amortization		7		693			700			1,379			1,399
Stock issued for services		9		1,238,513			-			1,238,513			45,000
Stock-based compensation				1,597			-			7,288			161,590
Change in non-cash operating working capital
Trade and other receivable				19,754			7,288			(21,355	)		3,109
Prepaid expenses				(241,270	)		(22,434	)		(247,764	)		(60,399	)
Deposits				(60,320	)		1,391			(29,846	)		(215,421	)
Accounts payable and accrued liabilities				417,477			(533,321	)		855,065			(223,028	)
				(2,740,495	)		(2,111,964	)		(4,448,289	)		(3,665,766	)
Cash flows from financing activities:
Cash proceeds from financing		9		4,002,496			3,000,000			4,002,496			3,250,000
Cash received from stock option exercises		10		30,522			22,395			1,438,308			39,544
Cash paid on stock issuance costs				(23,806	)		(25,260	)		(23,806	)		(34,124	)
Repayments of shareholder loan				-			-			-			(6,726	)
				4,009,212			2,997,135			5,416,998			3,248,694
Cash flows used in investing activities:
Investment in property and equipment		6		(124,474	)		(2,398	)		(137,693	)		(159,800	)
				(124,474	)		(2,398	)		(137,693	)		(159,800	)
Increase (decrease) in cash and cash equivalents				1,144,243			882,773			831,016			(576,872	)
Cash and cash equivalents, beginning of period				3,134,920			1,767,035			3,448,147			3,226,680
Cash and cash equivalents, end of period			$	4,279,163		$	2,649,808		$	4,279,163		$	2,649,808

The accompanying notes are an integral part of these condensed unaudited interim consolidated financial statements.

6 

1. Nature of operations and going concern

Zomedica Pharmaceuticals Corp. (the “Company”) was incorporated on January 7, 2013 under the Alberta Business Corporations Act as Wise Oakwood Ventures Inc. (“WOW”) and was classified as a capital pool company, as defined in Policy 2.4 of the TSX Venture Exchange.

On April 21, 2016, the Company closed its qualifying transaction (“Transaction”) with ZoMedica Pharmaceuticals Inc. (“ZoMedica”), and filed Articles of Amalgamation and amalgamated with 9674128 Canada Inc. which was wholly-owned by WOW. The amalgamated company changed its name to Zomedica Pharmaceuticals Ltd. and WOW subsequently changed its name to Zomedica Pharmaceuticals Corp. The shares of Zomedica Pharmaceuticals Corp. began trading under the new symbol “ZOM” on Monday May 2, 2016 on the TSX Venture Exchange. On June 21, 2016, the Company filed Articles of Amalgamation and vertically amalgamated with its wholly-owned subsidiary, Zomedica Pharmaceuticals Ltd.

Zomedica has one corporate subsidiary, Zomedica Pharmaceuticals, Inc., a Delaware company whose results and operations are included in these condensed unaudited interim consolidated financial statements. The Company is a biopharmaceutical company targeting health and wellness solutions for the companion pet through a ground-breaking approach that focuses on the needs of the veterinarians themselves. Zomedica's head office is located at 100 Phoenix Drive, Suite 190, Ann Arbor, MI 48108 and its registered office is located at Suite 1250, 639 – 5th Avenue S.W., Calgary, Alberta T2P 0M9.

Going concern

These condensed unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business and at amounts different from those in the accompanying condensed consolidated financial statements. Such adjustments could be material.

2. Basis of preparation

The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements.

Basis of consolidation

These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc.

All inter-company accounts and transactions have been eliminated on consolidation.

7 

3. Significant accounting policies

Use of estimates

The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.

Basis of measurement

The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.

Functional and reporting currencies

The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency.

The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.

Research and development

Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.

Translation of foreign currencies

In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.

Stock-based compensation

The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated.

8 

3. Significant accounting policies (continued)

Stock-based compensation (continued)

The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest.

The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Loss per share

Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not included in the computation of diluted EPS because the Company has incurred a loss for the six months ended June 30, 2018 as the effect would be anti-dilutive.

Comprehensive loss

The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. The Company has no other comprehensive loss items.

Future accounting pronouncements

In February 2016, the FASB issued new guidance, ASU No. 2016-02, Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic 842 is effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.

9 

4. Critical accounting judgments and key sources of estimation uncertainty

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Critical areas of estimation and judgements in applying accounting policies include the following:

Going concern

These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due.

Useful lives of property and equipment

As described in Note 3 above, the Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and revised service offerings. During the six month period ended June 30, 2018 and June 30, 2017, the Company was not required to adjust the useful lives of any assets based on the factors described above.

Deferred income taxes

The calculation of deferred income taxes is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets are reviewed at each balance sheet date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Stock-based payments

The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends.

10 

5. Prepaid expenses and deposits

The Company entered into a lease agreement with Wickfield Phoenix LLC effective on August 23, 2016. The Company prepaid the full outstanding balance of $801,973 on August 26, 2016 and recorded the prepaid rent due within a year as current. As at June 30, 2018, the Company has classified $155,220 as a current asset in the condensed unaudited interim consolidated balance sheet (December 31, 2017 - $155,220).

6. Property and equipment

	Computer equipment		Furniture and equipment		Laboratory equipment		Leasehold improvements		Total
Cost
Balance at December 31, 2016	$	61,598	$	7,364	$	243,529	$	25,672	$	338,163
Additions		89,557		68,694		2,200		11,285		171,736
Balance at December 31, 2017		151,155		76,058		245,729		36,957		509,899
Additions		22,763		4,172		110,758		-		137,693
Balance at June 30, 2018		173,918		80,230		356,487		36,957		647,592
Accumulated depreciation
Balance at December 31, 2016		13,858		1,490		29,783		3,998		49,129
Depreciation		28,944		10,355		45,092		5,222		89,613
Balance at December 31, 2017		42,802		11,845		74,875		9,220		138,742
Depreciation		20,284		5,754		20,558		17,562		64,158
Balance at June 30, 2018		63,086		17,599		95,433		26,782		202,900
Net book value as at:
December 31, 2017	$	108,353	$	64,213	$	170,854	$	27,737	$	371,157
June 30, 2018	$	110,832	$	62,631	$	261,054	$	10,175	$	444,692

7. Intangible assets

	Computer software		Trademarks		Total
Cost
Balance at December 31, 2016	$	5,143	$	16,236	$	21,379
Additions		-		-		-
Balance at December 31, 2017		5,143		16,236		21,379
Additions		-		-		-
Balance at June 30, 2018		5,143		16,236		21,379
Accumulated amortization
Balance at December 31, 2016		2,428		1,013		3,441
Amortization		1,715		1,082		2,797
Balance at December 31, 2017		4,143		2,095		6,238
Amortization		842		537		1,379
Balance at June 30, 2018		4,985		2,632		7,617
Net book value as at:
December 31, 2017	$	1,000	$	14,141	$	15,141
June 30, 2018	$	158	$	13,604	$	13,762

11 

8. Loan arrangements

On October 17, 2017, the Company entered into a loan arrangement with a shareholder of the Company, pursuant to which such shareholder has agreed to provide a loan facility to the Company, whereby the Company may borrow up to $5,000,000, with the proceeds to be used for working capital and general corporate purposes. The term of the loan facility is five (5) years, with principal and interest payments being due only at the time of maturity. Under the loan agreement, the Company may borrow in one or more advances, provided however that a minimum amount of $250,000 must be borrowed at any one time and not more than two advances may occur per month. Interest shall accrue at a rate of fourteen percent (14%) per annum, payable upon maturity. As of June 30, 2018, no amounts have been borrowed.

9. Capital stock

The Company is authorized to issue an unlimited number of common stock, all without par value.

Issued and outstanding common stock:

	Number of common stock		Capital stock
Balance at December 31, 2016		83,964,569	$	10,189,973
Stock issuance for services		43,613		45,000
Stock issued due to exercise of options		497,060		53,707
Stock issuance for financing, net of costs		2,902,682		3,215,876
Balance at June 30, 2017		87,407,924	$	13,504,556
Balance at December 31, 2017		90,225,869	$	18,244,659
Stock issuance for services (i)		641,717		1,238,513
Stock issued due to exercise of options (Note 10)		1,781,996		1,796,262
Stock issuance for financing, net of costs (ii)		1,861,627		3,978,690
Balance at June 30, 2018		94,511,209	$	25,258,124

i. On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

ii. On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

12 

10. Stock-based compensation

During the three months ended June 30, 2018, 154,000 options were exercised. During the three months ended June 30, 2017, 87,060 options were exercised. During the six months ended June 30, 2018, 1,781,996 options were exercised. During the six months ended June 30, 2017, 497,060 options were exercised and the Company issued 535,000 stock options, each option entitling the holder to purchase one common share of the Company.

The continuity of stock options are as follows:

	Number of Options			Weighted Avg Exercise Price (CDN$)
Balance at December 31, 2016		7,975,000			0.84
Stock options exercised on February 21, 2017		(10,000	)		0.25
Stock options exercised on February 21, 2017		(400,000	)		0.05
Options issued on February 24, 2017		535,000			1.50
Stock options exercised on May 8, 2017		(7,060	)		1.50
Stock options cancelled on May 17, 2017		(10,000	)		1.50
Stock options exercised on May 23, 2017		(80,000	)		0.25
Stock options exercised on July 6, 2017		(200,000	)		0.05
Stock options exercised on July 17, 2017		(220,000	)		0.25
Options issued on August 14, 2017		1,280,000			2.75
Stock options exercised on August 29, 2017		(7,940	)		1.50
Stock options exercised on December 19, 2017		(25,000	)		0.25
Stock options exercised on December 19, 2017		(750,000	)		1.50
Balance at December 31, 2017		8,080,000			1.21
Stock options exercised on January 8, 2018		(124,000	)		0.25
Stock options exercised on January 26, 2018		(100,000	)		0.25
Stock options exercised on March 8, 2018		(50,000	)		0.25
Stock options exercised on March 13, 2018		(176,000	)		0.25
Stock options exercised on March 22, 2018		(50,000	)		0.25
Stock options exercised on March 26, 2018		(240,000	)		0.25
Stock options exercised on March 28, 2018		(325,000	)		0.25
Stock options exercised on March 29, 2018		(562,996	)		2.75
Stock options exercised on April 20, 2018		(154,000	)		0.25
Stock options expired on April 21, 2018		(1,946,000	)		0.25
Stock options cancelled on June 8, 2018		(100,000	)		1.50
Stock options cancelled on June 21, 2018		(400,000	)		1.50
Balance at June 30, 2018		3,852,004			1.73

13 

10. Stock-based compensation (continued)

As at June 30, 2018, details of the issued and outstanding stock options are as follows:

Grant date	Exercise price (CDN$)		Number of options issued and outstanding		Number of vested options outstanding		Weighted Avg Remaining Life (years)
December 21, 2016	$	1.50		2,600,000		2,600,000		0.48
February 24, 2017	$	1.50		535,000		535,000		0.65
August 14, 2017 a	$	2.75		5,000		5,000		0.25
August 14, 2017 a	$	2.75		637,004		637,004		1.12
August 14, 2017 b	$	2.75		75,000		75,000		0.12

The fair value of options granted during the three and six months ended June 30, 2018 and year ended December 31, 2017 was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions:

	February 24, 2017		August 14, 2017 (a)		August 14, 2017 (b)
Volatility		59%		59%		83%
Risk-free interest rate		0.81%		1.22%		1.22%
Expected life (in years)		2		2		1
Dividend yield		0%		0%		0%
Common share price		CDN $1.35		CDN $2.40		CDN $2.40
Strike price		CDN $1.50		CDN $2.75		CDN $2.75
Forfeiture rate		nil		nil		nil

The Company recorded $1,597 of stock-based compensation for the three months ended June 30, 2018 (three months ended June 30, 2017 - $Nil). The Company recorded $7,288 of stock-based compensation for the six months ended June 30, 2018 (six months ended June 30, 2017 - $161,590). The Company recorded the cash receipt of $30,522 as capital stock and reclassified $6,517 of stock-based compensation to capital stock due to the exercise of 154,000 options during the three months ended June 30, 2018. The Company recorded the cash receipt of $1,438,308 as capital stock and reclassified $357,954 of stock-based compensation to capital stock due to the exercise of 1,781,996 options during the six months ended June 30, 2018.

Volatility is determined based on volatilities of comparable companies when the Company does not have its own sufficient trading history. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options.

The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is Nil as the Company is not expected to pay dividends in the foreseeable future. The Company has estimated its stock option forfeitures to be Nil for the three and six months ended June 30, 2018 (three and six months ended June 30, 2017 - $Nil).

11. Commitments and contingencies

Total future annual lease payments for the premises are as follows:

2018		8,696
Total	$	8,696

14 

12. Financial instruments

(a) Fair values

The Company follows ASC topic 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC topic 820 apply to other accounting pronouncements that require or permit fair value measurements. ASC topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a three level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refers broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument.

Level 3 inputs are unobservable inputs for asset or liabilities.

The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options.

An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options.

The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments.

(b) Interest rate and credit risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative to interest rates on cash and cash equivalents, due to related parties due to the short-term nature of these balances.

The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not subject to any external restrictions.

(c) Foreign exchange risk

The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the Canadian currency held by the Company versus the U.S. dollar would affect the Company’s loss and other comprehensive loss by $0.1 million.

15 

12. Financial instruments (continued)

(d) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.

The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at June 30, 2018 and December 31, 2017:

					June 30, 2018
	Less than 3 months	3 to 6 months	6 to 9 months	9 months 1 year	Greater than 1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	1,683,802	-	-	-	-	1,683,802
	1,683,802	-	-	-	-	1,683,802
					December 31, 2017
	Less than	3 to 6	6 to 9	9 months	Greater than
	3 months	months	months	1 year	1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	828,737	-	-	-	-	828,737
	828,737	-	-	-	-	828,737

13. Segmented information

The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion pet. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America (“US”).

	June 30, 2018		December 31, 2017
		$		$
Total assets
Canada		4,310,164		3,519,918
US		2,107,795		1,695,904
Total property and equipment
US		444,692		371,157

16 

14. Schedule of expenses

	For the three months ended June 30, 2018						For the three months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	174,067	$	-	$	859,268	$	189,091	$	-	$	414,567
Contracted expenditures		438,689		-		-		111,450		-		-
Marketing and investor relations		-		-		41,962		-		-		63,084
Travel and accommodation		3,547		-		70,463		991		-		100,443
Insurance		28,284		-		77,282		20,206		-		42,581
License fees		1,738,513		-		-		-		-		-
Office		3,129		-		61,460		3,767		-		19,897
Consultants		52,073		336,455		-		76,005		314,658		-
Regulatory		19,388		-		90,142		25,775		-		57,681
Rent		7,825		-		43,019		12,040		-		38,805
Supplies		69,105		-		4,894		64,910		-		11,551
Total	$	2,534,620	$	336,455	$	1,248,490	$	504,235	$	314,658	$	748,610

	For the six months ended June 30, 2018						For the six months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	326,439	$	-	$	1,502,555	$	360,002	$	-	$	971,430
Contracted expenditures		708,212		-		-		359,295		-		5,610
Marketing and investor relations		-		-		123,155		-		-		103,182
Travel and accommodation		5,336		-		191,868		2,958		-		178,785
Insurance		44,244		-		157,743		37,673		-		84,101
License fees		1,738,513		-		-		-		-		-
Office		34,646		-		138,406		11,868		-		50,165
Consultants		89,189		708,402		-		168,449		696,194		-
Regulatory		38,175		-		193,700		51,550		-		72,135
Rent		15,652		-		86,038		19,264		-		82,426
Supplies		134,554		-		15,196		109,625		-		27,800
Total	$	3,134,961	$	708,402	$	2,408,662	$	1,120,684	$	696,194	$	1,575,635

15. Capital risk management

The capital of the Company includes equity, which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

17 

16. Loss per share

	For the three months ended June 30,						For the six months ended June 30,
	2018			2017			2018			2017
Numerator
Net loss for the period	$	4,144,398		$	1,588,370		$	6,315,727		$	3,421,106
Denominator
Weighted average shares - basic		92,527,470			87,077,768			91,527,862			85,622,780
Stock options		-			-			-			-
Denominator for diluted loss per share		92,527,470			87,077,768			91,527,862			85,622,780
Loss per share - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.07	)	$	(0.04	)

For the above mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

17. Related party transactions and key management compensation

Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows:

	For the three months ended June 30,				For the six months ended June 30,
	2018		2017		2018		2017
Salaries and benefits, including bonuses	$	381,046	$	317,803	$	721,665	$	640,589
Stock-based compensation		-		-		-		151,020
Total	$	381,046	$	317,803	$	721,665	$	791,609

18 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, and those set forth in our most recent Annual Report on Form 10-K particularly those under “Risk Factors” discussed below and in our most recent Annual Report on Form 10-K.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

• the success, cost and timing of our research and development activities, validation studies and pivotal trials, including with respect to our lead product candidates, ZM-020, ZM-017, ZM-007, ZM-012, ZM-006 and ZM-011;

• our ability to obtain regulatory approval from the FDA-CVM and/or the USDA-CVB for our pharmaceutical and diagnostic product candidates, as applicable;

• our ability to obtain funding for our operations;

• the ability of our CROs to appropriately conduct our safety studies and certain development activities;

• the ability of our CMOs to manufacture and supply our product candidates in accordance with cGMP and our clinical needs;

• our plans to develop and commercialize any product candidates for which we receive regulatory approval;

• our ability to develop and commercialize product candidates that can compete effectively against the product candidates developed and commercialized by our competitors;

19 

• the size and growth of the veterinary diagnostics and therapeutics markets;

• our ability to obtain and maintain intellectual property protection for our current and future product candidates;

• regulatory developments in the United States;

• the loss of key scientific or management personnel;

• our expectations regarding the period during which we will be an “emerging growth company” under the JOBS Act;

• the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and

• our status as a PFIC for U.S. federal income tax purposes.

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements. Please see “Risk Factors” below and in our most recent Annual Report on Form 10-K for additional risks which could adversely impact our business and financial performance.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

20 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATION

Overview

We are a development stage veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline, and equine) by focusing on the unmet needs of clinical veterinarians. We believe that we have identified and are developing diagnostics and therapeutics that have the potential to significantly improve the diagnosis and treatment of various diseases affecting companion animals. We believe that there are significant unmet medical needs for pets, and that the pet diagnostic and therapeutic segments of the animal health industry are likely to grow substantially as new diagnostic tools and treatments are identified, developed, and marketed specifically for companion animals.

Together with our strategic partners, we are developing a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, liquid biopsy assays for the detection of cancer and related consumables. The regulatory pathway to obtain pre-market regulatory approval of companion animal diagnostics is significantly shorter than for similar diagnostic products intended for human use. In certain cases, pre-market regulatory approval may be unnecessary, depending on the intended use of the diagnostic.

We also have identified a number of drugs that have proven safe and effective in humans that we are developing for use in companion animals. We believe this development approach enables us to reduce the risks associated with obtaining regulatory approval for unproven product candidates and shortens the development timeline necessary to bring our product candidates to market. We have four drug product candidates in early development and have identified several other potential product candidates for further investigation.

In addition, we are investigating the development of alternative drug delivery technologies for our drug product candidates. Many of the human-approved therapeutics used in companion animals are only available in pill or injectable form. However, it can be difficult to give a companion animal an injection or to assure that the animal has swallowed a pill. As a result, we believe that compliance with treatment regimens is a significant problem for veterinarians and pet owners. The challenges associated with medicating pets are unique, and we believe that developing product candidates that can be easily taken by the pet or easily administered by pet owners will help increase compliance.

We are a development-stage company with no products approved for marketing and sale, and we have not generated any revenue. We have incurred significant net losses since our inception. We incurred net losses of $4,144,398 and $1,558,370 for the three months ended June 30, 2018 and June 30, 2017, respectively, and $6,315,727 and $3,421,106 for the six months ended June 30, 2018 and June 30, 2017, respectively. These losses have resulted principally from costs incurred in connection with investigating and developing our product candidates, research and development activities and general and administrative costs associated with our operations. As of June 30, 2018, we had an accumulated deficit of $21,941,827 and cash and cash equivalents of $4,279,163

For the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand our product development activities, commercialize them if they do not require U.S. Food and Drug Administration’s Center for Veterinary Medicine, or FDA-CVM, pre-market approval, and seek regulatory approvals for our product candidates where required from the FDA-CVM or the United States Department of Agriculture Center for Veterinary Biologics, or the USDA-CVB.

For further information on the regulatory, business and product pipeline, please see the “Business” section of the Annual Report on Form 10-K. For further information on the risk factors, please see the “Risk Factors” section of the Annual Report on Form 10-K.

21 

Revenue

We do not have any products approved for sale, have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties for any of our product candidates, we may generate revenue from those product candidates.

Operating Expenses

The majority of our operating expenses to date have been for the general and administrative activities related to general business activities, capital market activities and stock-based compensation, and research and development activities related to our lead product candidates.

Research and Development Expense

All costs of research and development are expensed in the period in which they are incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based compensation expense, fees paid to consultants, outside service providers, professional services, license fees, travel costs and materials used in clinical trials and research and development.

We have a point-of-care diagnostic platform, ZM-020, for the detection of pathogens in urine and fecal samples, and a non-invasive diagnostic assay or blood test, ZM-017, that we are developing as an aid for veterinarians in diagnosing cancer in canines.

We have four drug product candidates in development. Our lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms. Our second drug product candidate is ZM-012, a novel tablet formulation of metronidazole and a complementary formulation to ZM-007, targeting the treatment of acute diarrhea in larger dogs. Our third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats. Our fourth drug product candidate is ZM-011, a transdermal gel formulation of fluoxetine, most commonly known as Prozac®, its human pharmaceutical brand name.

We typically use our employee and infrastructure resources across multiple development programs. We track outsourced development costs by product candidate. We allocate personnel and other internal costs related to development of ZM-020 and ZM-017.

General and Administrative Expense

General and administrative expense consists primarily of personnel costs, including salaries, related benefits and stock-based compensation for employees, consultants and directors. General and administrative expenses also include rent and other facilities costs and professional and consulting fees for legal, accounting, tax services and other general business services.

Professional Fees

Professional fees include attorney’s fees, accounting fees and consulting fees incurred in connection with product investigation and analysis, regulatory analysis, government relations, audit, securities offerings, investor relations, and general corporate and intellectual property advice.

Income Taxes

As of December 31, 2017, we had net operating loss carryforwards for federal and state income tax purposes of $5,008,180 and non-capital loss carryforwards for Canada of approximately $6,526,850 respectively, which will begin to expire in fiscal year 2035. We have evaluated the factors bearing upon the realization of our deferred tax assets, which are comprised principally of net operating loss carryforwards and non-capital loss carryforwards. We concluded that, due to the uncertainty of realizing any tax benefits as of December 31, 2017, a valuation allowance was necessary to fully offset our deferred tax assets.

22 

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and revenue, costs and expenses and related disclosures during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 3 of the notes to our financial statements appearing elsewhere in this document, we believe that the estimates and assumptions involved in the following accounting policies may have the greatest potential impact on our financial statements.

JOBS Act

The Jumpstart Our Business Startups Act, or the JOBS Act, contains provisions that, among other things, reduce certain reporting requirements for an “emerging growth company.” We have irrevocably elected not to avail ourselves of the JOBS Act provision that an emerging growth company may delay adopting new or revised accounting standards until such times as those standards apply to private companies.

In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if as an “emerging growth company” we choose to rely on such exemptions, we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, and (ii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis). These exemptions will apply until December 31, 2022 or until we no longer meet the requirements of being an “emerging growth company,” whichever is earlier.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Actual results could differ from those estimates.

Areas where significant judgment is involved in making estimates are: the determination of the functional currency; the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; and forecasting future cash flows for assessing the going concern assumption.

Research and Development Costs

Research and development expenses comprise costs incurred in performing research and development activities, including salaries and benefits, safety and efficacy studies and contract manufacturing costs, contract research costs, patent procurement costs, materials and supplies and occupancy costs. Research and development activities include internal and external activities associated with research and development studies of current product candidates and advancing product candidates towards a goal of obtaining regulatory approval to manufacture and market the product candidate.

23 

Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.

Translation of Foreign Currencies

The functional currency, as determined by management, is U.S. dollars, which is also our reporting currency. Transactions denominated in currencies other than U.S. dollars and the monetary value of assets and liabilities are translated at the period end exchange rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated statements of operations and comprehensive loss.

Stock-Based Compensation

We measure the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by us cannot be reliably estimated.

We calculate stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of our stock-based compensation plans do not require us to settle any options by transferring cash or other assets, and therefore we classify the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. We estimate forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Volatility is determined based on volatilities of comparable companies as Company does not have its own trading history. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options. The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is Nil as we are not expected to pay dividends in the foreseeable future.

Loss Per Share

Basic loss per share, or EPS, is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

The dilutive effect of stock options is determined using the treasury stock method. Stock options and warrants to purchase our common shares issued during the period were not included in the computation of diluted EPS, as the effect would be anti-dilutive.

Comprehensive Loss

We follow ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. We currently have no other comprehensive loss items. 

24 

Results of Operations

Three and six months ended June 30, 2018 compared to three and six months ended June 30, 2017

Our results of operations for the three and six months ended June 30, 2018 and June 30, 2017 are as follows:

	Three months ended June 30,												Six months ended June 30,
	2018			2017			Change						2018			2017			Change
	$			$			$			%			$			$			$			%
Expenses
Research and development		2,534,620			504,235			2,030,385			403	%		3,134,961			1,120,684			2,014,277			180	%
General and administrative		1,248,490			748,610			499,880			67	%		2,408,662			1,575,635			833,027			53	%
Professional fees		336,455			314,658			21,797			7	%		708,402			696,194			12,208			2	%
Amortization		693			700			(7	)		-1	%		1,379			1,399			(20	)		-1	%
Depreciation		27,459			22,782			4,677			21	%		64,158			43,090			21,068			49	%
Loss from operations		4,147,717			1,590,985			2,556,732			161	%		6,317,562			3,437,002			2,880,560			84	%
Gain on settlement of liabilities		-			-			-			N/A			-			(5,000	)		5,000			N/A
Foreign exchange gain		(3,319	)		(2,615	)		(704	)		27	%		(1,835	)		(10,896	)		9,061			-83	%
Loss before income taxes		4,144,398			1,588,370			2,556,028			161	%		6,315,727			3,421,106			2,894,621			85	%
Income tax expense		-			-			-			N/A			-			-			-			N/A
Net loss and comprehensive loss		4,144,398			1,588,370			2,556,028			161	%		6,315,727			3,421,106			2,894,621			85	%

Revenue

We did not generate any revenue during the three and six months ended June 30, 2018 and June 30, 2017.

Research and Development

Research and development expense for the three months ended June 30, 2018 were $2,534,620 compared to $504,235 for the three months ended June 30, 2017, an increase of $2,030,385 or 403%. The increase was primarily due to the up-front licensing fee related to the signing of a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. of $1,738,513, and accrued payments to Seraph for previously incurred development costs of $333,247 included in contracted expenditures. The up-front licensing fee represented the issuance of unregistered common shares having a value of $1,238,513 and a cash payment of $500,000. Other significant expenditures include contracted expenditures of $438,689, and salaries, bonus and benefits of $174,067. However, there was also a reduction in salaries, bonus and benefits as we did not have a Chief Medical Officer in the three months ended June 30, 2018. Overall there was an increased level of lab activities, including in vitro and in vivo work, to support the further development of our product candidates ZM-017, ZM-020, ZM-007, ZM-012, ZM-006 and ZM-011.

Research and development expense for the six months ended June 30, 2018 were $3,134,961 compared to $1,120,684 for the six months ended June 30, 2017, an increase of $2,014,277 or 180%. The increase was primarily due to the up-front licensing fee related to the signing of a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. of $1,738,513, and accrued payments to Seraph for previously incurred development costs of $333,247 included in contracted expenditures. The up-front licensing fee represented the issuance of unregistered common shares having a value of $1,238,513 and a cash payment of $500,000. Other significant expenditures include contracted expenditures of $708,212, salaries, bonus and benefits of $326,439, and supplies of $134,554. However, there was also a reduction in salaries, bonus and benefits as we did not have a Chief Medical Officer in the six months ended June 30, 2018. Overall there was an increased level of lab activities, including in vitro and in vivo work, to support the further development of our product candidates ZM-017, ZM-020, ZM-007, ZM-012, ZM-006 and ZM-011. We expect that our R&D expenditures in 2018 will be significantly higher than in 2017, due to the upfront and milestone payments of licensed technologies, initiation of pilot and pivotal studies related to our four investigational new animal drug applications, work related to verification and validation of ZM-020 and ZM-017, and additional veterinary pharmaceutical candidates, diagnostic developments and technologies.

General and Administrative

General and administrative expense for the three months ended June 30, 2018 were $1,248,490, compared to $748,610 for the three months ended June 30, 2017, an increase of $499,880 or 67%. The increase was primarily due to significant expenses related to the addition of personnel, accounting for salaries of $859,268. Increases to salaries in the three months ended June 30, 2018 include the addition of a Chief Commercial Officer, a Vice President of Sales and accrued severance to a former officer of the Company. Other expenses included regulatory expense of $90,142, insurance costs of $77,282, travel and accommodation of $70,463, and office expenses of $61,460.

25 

General and administrative expense for the six months ended June 30, 2018 were $2,408,662, compared to $1,575,635 for the six months ended June 30, 2017, an increase of $833,027 or 53%. The increase was primarily due to significant expenses related to the addition of personnel, accounting for salaries of $1,502,555. Increases to salaries in the six months ended June 30, 2018 include the addition of a Chief Commercial Officer, a Vice President of Sales and accrued severance to a former an officer of the Company. Other expenses included regulatory expense of $193,700, travel and accommodation of $191,868, insurance costs of $157,743, office expenses of $138,406, and marketing and investor relations costs of $123,155. We expect that general and administrative expense will increase in 2018 and future periods as we increase our level of activity.

Professional Fees

Professional fees for the three months ended June 30, 2018 were $336,455 compared to $314,658 for the three months ended June 30, 2017, an increase of $21,797 or 7%. Professional fees for the 2018 period consisted primarily of consulting fees incurred in connection with preparation and completion of additional SEC filings and updates, and costs incurred in being a public company across two jurisdictions, Canada and U.S.

Professional fees for the six months ended June 30, 2018 were $708,402 compared to $696,194 for the six months ended June 30, 2017, an increase of $12,208 or 2%. Professional fees for the 2018 period consisted primarily of consulting fees incurred in connection with preparation and completion of additional SEC filings and updates, and costs incurred in being a public company across two jurisdictions, Canada and U.S.

Net Loss

Our net loss for the three months ended June 30, 2018 was $4,144,398, or $0.04 per share, compared with a net loss of $1,588,370, or $0.02 per share, for the three months ended June 30, 2017, an increase of $2,556,028 or 161%. The net loss in each period was attributed to the matters described above.

Our net loss for the six months ended June 30, 2018 was $6,315,727, or $0.07 per share, compared with a net loss of $3,421,106, or $0.04 per share, for the six months ended June 30, 2017, an increase of $2,894,621 or 85%. The net loss in each period was attributed to the matters described above. We expect to continue to record net losses in future periods until such time as have sufficient revenue from our product candidates to offset our operating expenses.

Cash Flows

Three and six months ended June 30, 2018 compared to three and six months ended June 30, 2017

The following table shows a summary of our cash flows for the periods set forth below:

	Three months ended June 30,											Six months ended June 30,
	2018			2017			Change					2018			2017			Change
		$			$			$		%			$			$			$		%
Cash flows used in operating activities		(2,740,495	)		(2,111,964	)		(628,531	)	30	%		(4,448,289	)		(3,665,766	)		(782,523	)	21	%
Cash flows from financing activities		4,009,212			2,997,135			1,012,077		34	%		5,416,998			3,248,694			2,168,304		67	%
Cash flows used in investing activities		(124,474	)		(2,398	)		(122,076	)	5091	%		(137,693	)		(159,800	)		22,107		-14	%
Increase (decrease) in cash		1,144,243			882,773			261,470		30	%		831,016			(576,872	)		1,407,888		-244	%
Cash and cash equivalents, beginning of period		3,134,920			1,767,035			1,367,885		77	%		3,448,147			3,226,680			221,467		7	%
Cash and cash equivalents, end of period		4,279,163			2,649,808			1,629,355		61	%		4,279,163			2,649,808			1,629,355		61	%

26 

Operating Activities

Net cash used in operating activities for the three months ended June 30, 2018 was $2,740,495 compared to $2,111,964 for the three months ended June 30, 2017, an increase of $628,531, or 30%. The increase resulted primarily from our net loss of $4,144,398 for the three months ended June 30, 2018, compared to our net loss of $1,588,370 for the three months ended June 30, 2017. The largest uses of cash stemmed from an increase in salaries, bonus and benefits as we had 20 employees at June 30, 2018, compared to 18 employees at June 30, 2017. Other significant increases in uses of cash include the Seraph up-front licensing fee cash payment of $500,000, increased regulatory and insurance expenses related to our listing on the NYSE American, and increased travel and accommodation expenses related to business development and pre-marketing activities.

Net cash used in operating activities for the six months ended June 30, 2018 was $4,448,289 compared to $3,665,766 for the six months ended June 30, 2017, an increase of $782,523, or 21%. The increase resulted primarily from our net loss of $6,315,727 for the six months ended June 30, 2018, compared to our net loss of $3,421,106 for the six months ended June 30, 2017. The largest uses of cash stemmed from an increase in salaries, bonus and benefits as we had 20 employees at June 30, 2018, compared to 18 employees at June 30, 2017. Other significant increases in uses of cash include the Seraph up-front licensing fee cash payment of $500,000, increased regulatory and insurance expenses related to our listing on the NYSE American, and increased travel and accommodation expenses related to business development and pre-marketing activities.

Net cash used in operating activities for the three and six months ended June 30, 2017 was $2,111,964 and $3,665,766, which resulted primarily from our net loss of $1,588,370 and $3,421,106. The largest uses of cash were for employee salaries, bonus and benefits, professional fees and consulting expenses related to the preparation of our initial U.S. registration statement, and work on our application to list our common shares on the NYSE American.

Financing Activities

Net cash provided by financing activities for the three months ended June 30, 2018 was $4,009,212 compared to net cash provided by financing activities of $2,997,135 for the three months ended June 30, 2017, an increase of $1,012,077, or 34%. The increase was due to cash proceeds from financing for $4,002,496 for the three months ended June 30, 2018, compared to $3,000,000 for the three months ended June 30, 2017.

Net cash provided by financing activities for the six months ended June 30, 2018 was $5,416,998 compared to net cash provided by financing activities of $3,248,694 for the six months ended June 30, 2017, an increase of $2,168,304, or 67%. The increase resulted from the proceeds from the exercise of stock options for $1,438,308 for the six months ended June 30, 2018, compared to only $39,544 for the six months ended June 30, 2017. The increase was also due to cash proceeds from financing for $4,002,496 for the six months ended June 30, 2018, compared to $3,250,000 for the six months ended June 30, 2017.

Net cash provided by financing activities for the three and six months ended June 30, 2017 was $2,997,135 and $3,248,694, which relates to the sale of $3,250,000 of our common shares and proceeds from the exercise of stock options for $39,544, partially offset by repayment on a shareholder loan of $6,726 and stock issuance costs of $34,124.

Investing Activities

Net cash used in investing activities for the three months ended June 30, 2018 was $124,474, compared to $2,398 for the three months ended June 30, 2017, an increase of $122,076, or 5091%. The increase resulted primarily from the addition of laboratory equipment used for the development of ZM-017.

Net cash used in investing activities for the six months ended June 30, 2018 was $137,693, compared to $159,800 for the six months ended June 30, 2017, a decrease of $22,107, or 14%. The decrease resulted primarily from the completion of build-out of the new office space in Ann Arbor.

27 

Net cash used in investing activities for the three and six months ended June 30, 2017 was $2,398 and $159,800, which primarily resulted from leasehold improvements and the purchase of furniture and equipment for our additional office space in Ann Arbor.

Liquidity and Capital Resources

We have incurred losses and negative cash flows from operations and have not generated any revenue since our inception in May 2015. As of June 30, 2018, we had an accumulated deficit of $21,941,827. We have funded our working capital requirements primarily through the sale of our common shares and the exercise of stock options. At June 30, 2018, we had cash and cash equivalents of $4,279,163.

Working capital (defined as current assets minus current liabilities) was $3,780,222 as at June 30, 2018. This was primarily due to cash and cash equivalents of $4,279,163 and prepaid expenses and deposits of $1,135,234, partially offset by accounts payables and accrued liabilities of $1,683,802.

On October 17, 2017 we entered into a five-year $5,000,000 unsecured working capital facility with Equidebt LLC, one of our shareholders (the “Equidebt Facility”). Amounts borrowed under the Equidebt Facility bear interest at a rate of 14% per annum payable at maturity. All amounts borrowed under the Equidebt Facility become due and payable on October 17, 2022. We can make two borrowing per month under the Equidebt Facility, each of which must be for a minimum of $250,000. The Equidebt Facility is unsecured; however Gerald A. Solensky Jr., our Chairman of the Board, President and Chief Executive Officer, has personally guaranteed our obligations under the Equidebt Facility.

On May 15, 2018, we announced a private offering of up to $10,000,000 of our common shares at a price of $2.15 per share (the “Private Placement”) and we issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, we issued an additional 1,605,812 common shares for gross proceeds of $3,452,496 pursuant to the Private Placement. On July 28, 2018 the Private Placement of common shares expired with no additional sales. In aggregate, we sold a total of 1,861,627 common shares at a price of $2.15 per share for total gross proceeds of approximately $4,002,496. These common shares may not be offered or sold in the United States unless they are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

We believe that our existing cash and available borrowings under the Equidebt Facility will be sufficient to fund our operations through the next twelve months. Our ability to continue as a going concern is ultimately dependent upon our ability to achieve sustainable positive cash flow from operations. However, we do not expect to generate revenue from the sale of our product candidates for the foreseeable future. To the extent that we do not generate sufficient cash flow from our operations, we intend to finance our working capital requirements through equity and/or debt financings, development agreements or marketing license agreements, the collection of revenues resulting from future commercialization activities and/or new strategic partnership agreements. There can be no assurance that we will be able to obtain any such capital on terms or in amounts sufficient to meet our needs or at all. The availability of equity or debt financing will be affected by, among other things, the results of our research and development activities, our ability to obtain regulatory approvals, market acceptance of any products for which we receive marketing approval, conditions in the capital markets generally and in the veterinary products industry, strategic alliance agreements and other relevant commercial considerations.

If we raise additional funds by issuing equity securities, our existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that could restrict operations. In the event that we are unable to obtain sufficient capital to meet our working capital requirements, we may be required to change or curtail current or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated. In such an event, we may not be able to take advantage of business opportunities, and may have to terminate or delay safety and efficacy studies, curtail our product development programs, or sell or assign rights to our product candidates, products and technologies.

28 

Based on the closing price of our common shares on June 30, 2018, the market price of our common shares exceeded the exercise price of our outstanding stock options. To the extent that some or all of such stock options are exercised, we would receive the proceeds of such exercises which would provide additional capital for our company. However no assurance can be given that any of such stock options will be exercised or as to the proceeds and timing of any exercises that do occur. The willingness of option holders to exercise their options depends on a number of factors, including, without limitation: the future market price of our common shares; the availability of capital to fund the payment of the exercise price of such options, the tax consequences of any such exercises and the ability of such option holders to resell some or all of the common shares received upon such exercises.

Our future capital requirements depend on many factors, including, but not limited to:

• the scope, progress, results and costs of researching and developing our current or future product candidates;

• the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;

• the number and characteristics of the product candidates we pursue;

• the cost of manufacturing our current and future product candidates and any products we successfully commercialize;

• the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing, sales, service, customer support and distribution costs;

• the expenses needed to attract and retain skilled personnel;

• the costs associated with being a public company;

• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements; and

• the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

Off Balance Sheet Arrangements

Since inception, we have not engaged in the use of any off-balance sheet arrangements, such as structured finance entities, special purpose entities or variable interest entities.

Recent Accounting Pronouncements

In February 2016, the FASB issued new guidance, ASU No. 2016-02, Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic 842 is effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption is permitted. We are in the process of evaluating the amendments to determine if they have a material impact on our financial position, results of operations, cash flows or disclosures.

29 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Evaluation of Our Disclosure Controls

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive officer and our chief financial officer, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2018, our disclosure controls and procedures were effective.  

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in the framework in “Internal Control — Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of June 30, 2018.

30 

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors.

RISK FACTORS

Risks Related to Our Business

We have a limited operating history, are not profitable and may never become profitable.

We are a development stage veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Since the commencement of our business in May 2015, our operations have been primarily limited to the identification of product candidates and research and development of our diagnostic and drug product candidates, ZM-020, a Raman spectroscopy-based point-of-care diagnostic platform, ZM-017, a non-invasive diagnostic assay or blood test for the detection of certain cancers in canines, ZM-007 and ZM-012, an anti-diarrheal oral suspension and pill form respectively that is intended for use in dogs, ZM-006, a transdermal gel treatment for hyperthyroidism, a metabolic disorder, which is intended for use in cats and ZM-011, a transdermal gel treatment for behavioral disorders intended for use in cats. As a result, we have limited historical operations upon which to evaluate our business and prospects and we have not yet demonstrated an ability to obtain approval for any of our product candidates or successfully overcome the risks and uncertainties frequently encountered by companies in emerging fields such as the companion animal pharmaceuticals and health care solutions industries.

We also have not generated any revenue to date, and we expect to continue to incur significant research and development costs and other expenses. Our net loss and comprehensive loss for the three months ended June 30, 2018 and June 30, 2017 was $4,144,398 and $1,588,370, respectively, for the six months ended June 30, 2018 and June 30, 2017 was $6,315,727 and $3,421,106, respectively, and for the years ended December 31, 2017 and December 31, 2016 was $8,065,072 and $5,740,492, respectively. Our accumulated deficit as of June 30, 2018 was $21,941,827. As of June 30, 2018, we had total shareholders' equity of $4,734,157. We expect to continue to incur losses for the foreseeable future, which will increase significantly from historical levels as we expand our product development activities (including conducting required clinical studies and trials), seek necessary approvals for our product candidates, and begin commercialization activities. Even if we succeed in developing and broadly commercializing one or more of our product candidates, we expect to continue to incur losses for the foreseeable future, and we may never become profitable. If we fail to achieve or maintain profitability, then we may be unable to continue our operations at planned levels and be forced to reduce or cease operations.

We will need to raise additional capital to achieve our goals.

We do not have any products approved for sale. Although we believe that we do not require pre-market approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine, or the FDA-CVM, to market and sell ZM-020, our Raman spectroscopy-based point-of-care diagnostic platform, or ZM-017, the circulating tumor cell, or CTC, diagnostic assay that we are developing, we do not expect to commence marketing of these solutions until the second half of 2018.

Until, and unless, we receive approval from the FDA-CVM for our drug product candidates, we cannot market or sell our drug products in the United States and will have no material drug product revenue. Our lead drug product candidates, ZM-007, ZM-012, ZM-006 and ZM-011 are in the formulation, optimization and/or pilot study stage, and we have not yet begun pivotal trials. We anticipate that each of our drug product candidates will require from three to five years of development at a cost of approximately $3 million to $5 million per drug product candidate before we expect to be able to apply for marketing approval in the United States.

We are also seeking to identify potential complementary opportunities in the veterinary diagnostics and therapeutics sectors. We will continue to expend substantial resources for the foreseeable future to develop our existing product candidates and any other product candidates that we may develop or acquire. These expenditures will include: costs of identifying additional potential product candidates; costs associated with drug formulation; costs associated with conducting pilot and pivotal trials and clinical studies; costs associated with completing other research and development activities; costs associated with payments to technology licensors and maintaining other intellectual property; costs of obtaining regulatory approvals; costs associated with securing contract manufacturers to meet our commercial manufacturing and supply capabilities; and costs associated with marketing and selling any of our products approved for sale. We also may incur unanticipated costs. Because the outcome of our development activities and commercialization efforts is inherently uncertain, the actual amounts necessary to successfully complete the development and commercialization of our existing or future product candidates may be greater or less than we anticipate.

31 

As a result, we will need to obtain additional capital to fund the development of our business. Except for our $5,000,000 unsecured working capital loan we have no existing agreements or arrangements with respect to any financings, and any such financings may result in dilution to our shareholders, the imposition of debt covenants and repayment obligations or other restrictions that may adversely affect our business or the value of our common shares.

Our future capital requirements depend on many factors, including, but not limited to:

• the scope, progress, results and costs of researching and developing our existing or future diagnostics and product candidates;

• the timing of, and the costs involved in, obtaining regulatory approvals for any of our existing or future diagnostics or product candidates;

• the number and characteristics of the diagnostics and/or product candidates we pursue;

• the cost of contract manufacturers to manufacture our existing and future diagnostics and product candidates and any products we successfully commercialize;

• the cost of commercialization activities if any of our existing or future diagnostics and product candidates are approved for sale, including marketing, sales and distribution costs;

• the expenses needed to attract and retain skilled personnel;

• the costs associated with being a public company;

• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements; and

• the costs involved in preparing and filing patent applications, maintaining any successfully obtained patents and protecting and enforcing any such patents.

Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate one or more of our product development programs or any future commercialization efforts.

We are substantially dependent on the success of our lead product candidates, and cannot be certain that any of them will be approved for marketing, to the extent applicable, or successfully commercialized.

We have no products approved for sale in any jurisdiction and are focused primarily on the development of our lead diagnostic and drug product candidates, ZM-020, ZM-017, ZM-007, ZM-012, ZM-006 and ZM-011. Accordingly, our near-term prospects, including our ability to generate material product revenue, or enter into potential strategic transactions, will depend heavily on the successful development and commercialization of one or more of our lead candidates, which in turn will depend on a number of factors, including the following:

• the successful completion of clinical validation of our diagnostic product candidates, which may take significantly longer than we anticipate and will depend, in part, upon the satisfactory performance of third-party contractors;

32 

• the successful completion of pilot testing and pivotal efficacy and safety trials of one or more of our drug product candidates, which may take significantly longer than we anticipate and will depend, in part, upon the satisfactory performance of third-party contractors;

• our ability to demonstrate to the satisfaction of the FDA-CVM or the USDA Center for Veterinary Biologics, or USDA-CVB, as applicable, the safety and efficacy of our drug product candidates and to obtain regulatory approvals;

• the ability of our third-party contract manufacturers to manufacture supplies of any of our product candidates and to develop, validate and maintain viable commercial manufacturing processes that are compliant with Good Manufacturing Practices or GMP;

• our ability to successfully market any product candidate for which marketing approval is received, whether alone or in collaboration with others;

• the availability, perceived advantages, relative cost, relative safety and relative efficacy of our product candidates compared to alternative and competing treatments;

• the acceptance of our product candidates as safe and effective by veterinarians, pet owners and the animal health community;

• our ability to achieve and maintain compliance with all regulatory requirements applicable to our business; and

• our ability to obtain and enforce our intellectual property rights and obtain marketing exclusivity for our product candidates, and avoid or prevail in any third-party patent interference, patent infringement claims or administrative patent proceedings initiated by third parties or the United States Patent and Trademark Office (“USPTO”).

Many of these factors are beyond our control. Accordingly, we cannot assure you that we will be successful in developing or commercializing any of our product candidates. If we are unsuccessful or are significantly delayed in developing and commercializing ZM-020, ZM-017, ZM-007, ZM-012, ZM-006 or ZM-011 or any of our other product candidates, our business and prospects will be materially adversely affected and you may lose all or a portion of your investment. 

Our product candidates will face significant competition and may be unable to compete effectively.

The development and commercialization of veterinary diagnostics and pharmaceuticals is highly competitive and our success depends on our ability to compete effectively with other products in the market.

There are a number of competitors in the diagnostic market that have substantially greater financial and operational resources and established marketing, sales and service organizations. We expect to compete primarily with commercial clinical laboratories, hospitals’ clinical laboratories and other veterinary diagnostic equipment manufacturers. Our principal competitors in the veterinary diagnostic market are Idexx Laboratories, Inc., Antech Diagnostics, a unit of VCA Inc., Abaxis, Inc., Heska Corporation and Zoetis Inc. We must develop our distribution channels and build our direct sales force in order to compete effectively in these markets. If we are unable to effectively manage our distribution channels in our highly competitive industry, we may fail to retain customers or obtain new customers and our business will suffer.

If our drug product candidates are approved, we expect to compete with large animal health companies including Merck Animal Health, the animal health division of Merck & Co., Inc.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH; and Zoetis, Inc., as well as European companies such as Virbac S.A., Vetoquinol S.A. and Dechra Pharmaceuticals PLC We are also aware of several smaller early stage companies that are developing products for use in the pet therapeutics market, including Kindred Biosciences, Inc., Aratana Therapeutics, Inc., Parnell Pharmaceuticals Holdings Ltd. and Jaguar Animal Health, Inc. We also expect to compete with academic institutions, governmental agencies and private organizations that are conducting research in the field of animal health medicines.

33 

We target drug product candidates for which the API, while having been approved for use in human drugs, has not been previously approved for use in animals. If we are the first to gain approval for the use of such API in animals, our drug products will benefit from between three and seven years of marketing exclusivity in the United States for the approved indication. We also plan to differentiate our products, where possible, with alternative drug delivery systems that are more conducive to dosing for the target companion animal species, but we cannot assure you that we will be able to prevent our competitors from developing substantially similar products and bringing those products to market earlier than we are able to.

Our drug product candidates will face competition from various products approved for use in humans that are used off-label in animals, and all of our products will face potential competition from new products in development. These and other potential competing products may benefit from greater brand recognition and brand loyalty than our drug product candidates may achieve.

Many of our competitors and potential competitors have substantially more financial, technical and human resources than we do. Many also have far more experience than we have in the development, manufacture, regulation and worldwide commercialization of animal health medicines, including pet therapeutics. We also expect to compete with academic institutions, governmental agencies and private organizations that are conducting research in the fields of animal diagnostics and animal health. If such competing products are commercialized prior to our product candidates, or if our intellectual property protection and efforts to obtain regulatory exclusivity fail to provide us with exclusive marketing rights for some of our therapeutic products, we may be unable to compete effectively in the markets in which we participate. Contractual agreements between clinics and from competitors may limit practices’ ability to use other tests and technologies due to predetermined minimums in those agreements.

Development of product candidates for use in companion animal health is an inherently expensive, time-consuming and uncertain, and any delay or discontinuance of validation or pivotal studies for our current or future product candidates would significantly harm our business and prospects.

Development of product candidates for use in companion animals is an inherently lengthy, expensive and uncertain process, and there is no assurance that our development activities will be successful. We do not know whether the validation studies of ZM-017 or ZM-020, or the pivotal studies of ZM-007, ZM-012, ZM-006 or ZM-011, or of any of our other product candidates, will begin or conclude on time, and they may be delayed or discontinued for a variety of reasons, including if we are unable to:

• address any safety concerns that arise during the course of the studies;

• complete the studies due to deviations from the study protocols,  the occurrence of adverse events or, in the case of our validation studies, sensitivity and selectivity results that vary from our expectations;

• add new study sites;

• address any conflicts with new or existing laws or regulations; or

• reach agreement on acceptable terms with study sites, which can be subject to extensive negotiation and may vary significantly among different sites.

Any delays in completing our development efforts will increase our costs, delay our product candidate development and any regulatory approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, factors that may cause a delay in the commencement or completion of our development efforts may also ultimately lead to the denial of regulatory approval of our product candidates which, as described above, would materially, adversely impact our business and prospects.

34 

We will rely on third parties to conduct certain portions of our development activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates.

We have used contract manufacturing organizations (“CMOs”) and contract research organizations (“CROs”) to conduct our manufacturing and research and development activities. We expect to continue to do so, including with respect to our manufacturing, clinical validation, pilot studies and pivotal trials of ZM-020, ZM-017, ZM-007, ZM-012, ZM-006 and ZM-011. These CMOs and CROs are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs or manage the risks associated with their activities on our behalf. We are responsible to regulatory authorities for ensuring that each of our product candidates is manufactured using good manufacturing practices and studies are conducted in accordance with the development plans and trial protocols, and any failure by our CMOs and CROs to do so may adversely affect our ability to obtain regulatory approvals, subject us to penalties, or harm our credibility with regulators. The FDA-CVM also requires us and our CMOs and CROs to comply with regulations and standards, commonly referred to as good manufacturing practices, or GMPs, good clinical practices, or GCPs, and good laboratory practices, or GLPs, collectively called GXPs, for conducting, monitoring, recording and reporting the results of our manufacturing and studies to ensure that the data and results are scientifically credible and accurate.

Our agreements with our CMOs and CROs may allow termination by the CMOs and CROs in certain circumstances with little or no advance notice to us. These agreements generally will require our CMOs and CROs to reasonably cooperate with us at our expense for an orderly winding down of the CMOs’ and CROs’ services under the agreements. If the CMOs and CROs conducting our manufacturing and studies do not comply with their contractual duties or obligations to us, or if they experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our development protocols or GXPs or for any other reason, we may need to secure new arrangements with alternative CMOs and CROs, which could be difficult and costly. In such event, our studies also may need to be extended, delayed or terminated as a result, or may need to be repeated. If any of the foregoing were to occur, regulatory approval and commercialization of our product candidates may be delayed and we may be required to expend substantial additional resources.

The failure of any CMO and CRO to perform adequately or the termination of any arrangements with any of them may adversely affect our business.

Risks Related to Government Regulation

Various government regulations could limit or delay our ability to develop and commercialize our products or otherwise negatively impact our business.

In the U.S., the manufacture and sale of certain diagnostic products are regulated by agencies such as the USDA, the FDA or the EPA. While our point-of-care Raman spectroscopy-based diagnostic solution and our diagnostic test for canine cancer do not require approval by the USDA prior to sale in the U.S., these diagnostic solutions will be subject to post-marketing oversight by the FDA-CVM. In addition, delays in obtaining regulatory approvals for new products or product upgrades could have a negative impact on our growth and profitability.

The manufacture and sale of our products, as well as our research and development processes, are subject to similar and potentially more stringent laws in foreign countries.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products; our business practices in the U.S. and abroad, such as anti-corruption and anti-competition laws; and immigration and travel restrictions. These legal and regulatory requirements differ among jurisdictions around the world and are rapidly changing and increasingly complex. The costs associated with compliance with these legal and regulatory requirements are significant and likely to increase in the future.

35 

Any failure to comply with applicable legal and regulatory requirements could result in fines, penalties and sanctions; product recalls; suspensions or discontinuations of, or limitations or restrictions on, our ability to design, manufacture, market, import, export or sell our products; and damage to our reputation.

Risks Related to Intellectual Property

Our diagnostic assay technologies depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from marketing our diagnostic product candidates.

Our Raman spectroscopy-based point-of-care diagnostic product is dependent on a license from Seraph Biosciences, Inc., while our canine cancer diagnostic assay technology is dependent on a license from Celsee, Inc. We do not own the intellectual property rights that underlie these licenses. Our rights to use the technology we license are subject to the negotiation of, continuation of and compliance with the terms of our licenses. We do not control the prosecution, maintenance or filing of the patents and other intellectual property licensed to us, or the enforcement of these intellectual property rights against third parties. The patents and patent applications underlying our licenses were not written by us or our attorneys, and we do not have control over the drafting and prosecution of such rights. Seraph and Celsee might not have given the same attention to the drafting and prosecution of patents and patent applications as we would have if we had been the owners of the intellectual property rights and had control over such drafting and prosecution. We cannot be certain that drafting and/or prosecution of the licensed patents and patent applications has been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.

36 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On May 15, 2018 the Company completed an interim closing of it private offering of common shares, resulting in the sale of 255,815 common shares at a price of $2.15 per share for gross proceeds of $550,000. On June 28, 2018 the Company completed an interim closing of it private offering of common shares, resulting in the sale of 1,605,812 common shares at a price of $2.15 per share for gross proceeds of $3,452,496. On July 28, 2018 the private offering of common shares expired with no additional sales. In aggregate, we sold a total of 1,861,627 common shares at a price of $2.15 per share for total gross proceeds of approximately $4,002,500.

The issuance of the common shares to the investors was exempt from registration under the Securities Act of 1933, as amended pursuant to Regulation D and Section 4(a)(2) and/or Regulation S thereof and such other available exemptions. As such, the common shares may not be offered or sold in the United States unless they are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available.

Use of Proceeds

We will use the proceeds of this offering for working capital and general corporate purposes, including the ongoing development of its product candidates.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.

37 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zomedica Pharmaceuticals Corp.
By:	/s/ Gerald Solensky, Jr.
Name:	Gerald Solensky Jr.
Title:	Chief Executive Officer
By:	/s/ Shameze Rampertab
Name:	Shameze Rampertab
Title:	Chief Financial Officer

38 

EXHIBIT INDEX

Exhibit No.	Description
3.1	Articles of Amalgamation of Zomedica Pharmaceuticals Corp. (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form S-1 filed with the Commission on April 21, 2017 (File No. 333-217409))
3.2	Amended and Restated By-Law No. 1 of Zomedica Pharmaceuticals Corp. (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form S-1 filed with the Commission on April 21, 2017 (File No. 333-217409))
3.3	Certificate of Amendment and Registration of Restated Articles of Zomedica Pharmaceuticals Corp. (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form S-1 filed with the Commission on April 21, 2017 (File No. 333-217409))
3.4	Certificate of Amalgamation of Zomedica Pharmaceuticals Corp. (incorporated by reference to Exhibit 3.4 to the Company's Registration Statement on Form S-1 filed with the Commission on April 21, 2017 (File No. 333-217409))
10.24#	Development, Commercialization and Exclusive Distribution Agreement, dated May 10, 2018, by and between Seraph Biosciences, Inc. and Zomedica Pharmaceuticals Corp.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
101.INS	XBRL Instance Document.*
101.SCH	XBRL Taxonomy Extension Schema Document.*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.*

* This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

# The registrant has sought confidential treatment with respect to certain portions of this exhibit

39

EX-10.24

Exhibit 10.24

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

CONFIDENTIAL

DEVELOPMENT, COMMERCIALIZATION AND EXCLUSIVE DISTRIBUTION AGREEMENT

THIS DEVELOPMENT, COMMERCIALIZATION AND EXCLUSIVE DISTRIBUTION AGREEMENT is made as of May 10, 2018 (the "Effective Date"), between Seraph Biosciences, Inc., a Delaware corporation with its principal place of business at 1449 Woodward Avenue, #2-108, Detroit, Michigan 48226 ("Seraph") and Zomedica Pharmaceuticals Corp., a corporation organized pursuant to the laws of Alberta, Canada, having offices at 100 Phoenix Drive, Suite 190, Ann Arbor, Michigan 48108 ("Zomedica").

Background

WHEREAS, Seraph has developed certain technology and owns or controls certain intellectual property relating to its Seraspec® hardware platform and associated software (the "Seraspec Platform"), and the consumables developed by Seraph and used in conjunction with the Seraspec Platform (the "Seraspec Consumables"); and

WHEREAS, Seraph has received a license from Wayne State University to certain patents and technology related to the detection and identification of certain protein based compounds which are included in the Seraspec Technology (as hereinafter defined); and

WHEREAS, Zomedica is a veterinary pharmaceutical and health care solutions company creating innovative products for companion animals (canine, feline and equine) including veterinary-approved drugs, novel drug-delivery technologies and diagnostics, and which has expertise and know-how in developing products for applications in the veterinary field; and

WHEREAS, the Parties desire to establish a collaboration for the development and validation of a Seraspec® Platform device and Seraspec Consumables carrying a Zomedica brand (the "Product"), for use in the Zomedica Field of Use (as defined below) in the Territory (as defined below), upon the terms and conditions set forth in this Agreement.

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows:

Terms and Conditions

1.Definitions.

(a)"Affiliate" means, with respect to a Person, any Person that controls, is controlled by or is under common control with such first Person. For the purposes of this definition only, "control" means (i) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or (ii) to own, directly or indirectly, fifty percent (50%) or more of the outstanding securities or other ownership interest of such Person.

(b)"Agreement" means this Development, Commercialization and Exclusive Distribution Agreement.

(c)"Bankrupt Party" has the meaning set forth in Section 11(f) of this Agreement.

(d)"Basic Purchase Order Terms" means, collectively, any one or more of the following terms specified by Zomedica in a Purchase Order pursuant to Section 4(d): (i) an itemized list of the Seraspec Platforms and Seraspec Consumables to be purchased; (ii) the quantity of each ordered; (iii) the requested delivery date; (iv) the Supply Price for each item to be purchased; (v) the billing address; and (vi) the delivery location. For the avoidance of doubt, the term "Basic Purchase Order Terms" does not include any general terms or conditions of any Purchase Order.

(e)"Change in Control" means: (i) any merger, amalgamation, consolidation or other similar business combination transaction of a Party with or into any third party Person (other than for the purpose of changing the name or the jurisdiction of organization of the Party) in which the shareholders of the Party immediately prior to the transaction cease to own at least 50% of the outstanding voting power of the Party or the Person surviving such transaction; (ii) the acquisition, directly or indirectly, by any Person and such Person's Affiliates (other than, in the case of Zomedica, Gerald A. Solensky, Jr., his Affiliates, and his heirs and legal representatives) of the power to direct or cause the direction of the management and policies of a Party, whether through the ownership of voting securities, by contract or otherwise, including, without limitation, the direct or indirect acquisition of 50% or more of the outstanding voting power of a Party; and (iii) the sale, lease, exclusive license or other transfer by a Party of all or substantially all of the assets of a Party to any third party Person, in one or a series of related transactions. "Change in Control" shall not include any Change in Control required by a government or the requirements of applicable law, or a transaction or series of transactions principally undertaken for bona fide equity financing purposes.

(f)"Commercially Reasonable Efforts" of a Party means, with respect to an obligation of a Party to accomplish an objective under this Agreement, the efforts and resources comparable to those undertaken by a veterinary pharmaceutical company of comparable size and resources in the case of Zomedica or a biotechnology company of comparable size and resources in the case of Seraph, in either case, relating to the research, development or commercialization of a similar product owned by such company, or to which such company has exclusive rights, with comparable market potential and is at a similar stage in its lifecycle. For this purpose, all relevant factors, as measured by the facts and circumstances at the time such efforts are due, shall be taken into account, including, as applicable and without limitation, stage of development; efficacy and safety relative to competitive products in the marketplace; actual or anticipated regulatory approval; labeling; the nature and extent of market exclusivity (including patent coverage, proprietary position and regulatory exclusivity), product pricing and reimbursement; and the cost and time required for and likelihood of obtaining regulatory approval and commercializing a product.

2

(g)"Competitor" means an entity primarily engaged in the same or similar business as a Party.

(h)"Confidential Information" means information, materials, data and results, in whatever form, that the disclosing Party (the "Disclosing Party") considers secret and/or valuable proprietary information, including, without limitation, proprietary technical, process, operational, business, financial and other trade secret information and know-how and sample materials related to their respective businesses. Confidential Information shall not, however, include any information which the receiving Party (the "Receiving Party") can demonstrate with competent proof: (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the Disclosing Party; (ii) becomes publicly known and made generally available after disclosure by the Disclosing Party to the Receiving Party through no misconduct of the Receiving Party; (iii) is already in the possession of the Receiving Party without confidentiality obligations at the time of disclosure by the Disclosing Party as shown by the Receiving Party’s contemporaneous records; (iv) is obtained by the Receiving Party from a third party without a breach of such third party’s obligations of confidentiality; or (v) is independently developed by the Receiving Party without use of or reference to the Confidential Information of the Disclosing Party.

(i)"Cost of Purchase" means Seraph's actual cost to purchase the Seraspec Platform or the Seraspec Consumables, as the case may be, from its suppliers.

(j)"Development Costs" means all development, validation and other pre-market costs incurred in connection with the execution of the Development Plan and as set forth in the Statements of Work, including without limitation, the costs of the proof of concept studies and clinical validation studies, and the research and validation costs incurred by Seraph identified in the Statements of Work. Development Costs shall be based on a full accounting of development and validation costs described in the applicable Statement of Work, including reimbursements and payments made by Zomedica to Seraph, and shall be agreed upon by the Parties prior to commercialization.

(k)"Development Data and Documentation" means all data and documentation produced in the course of the Parties' activities under this Agreement, but excluding Veterinary-Specific Data and Documentation, including without limitation, data and documentation relating to the following items: (i) verification and validation protocols and data collection standards; (ii) Pathogen-Specific Data and Documentation; (iii) limits of detection verification results; and (iv) negative control verification results (confounding pathogens/pseudo pathogens).

(l)"Development Plan" has the meaning set forth in Section 3(a) of this Agreement.

(m)"Effective Date" has the meaning set forth in the introductory paragraph of this Agreement.

(n)"Event of Bankruptcy" means (i) the filing, with any court or agency pursuant to any statute or regulation of any state or country of, (1) a petition in bankruptcy or insolvency, (2) for reorganization or (3) for the appointment of (or for an arrangement for the appointment of) a receiver or trustee of the Bankrupt Party or of its asset; (ii) with respect to the Bankrupt Party, being served with an involuntary petition filed in any insolvency proceeding, which such petition is not dismissed within sixty (60) days after the filing thereof; (iii) proposing or being party to any dissolution or liquidation when insolvent; or (iv) making an assignment for the benefit of creditors.

3

(o)"Excess Gross Profit" has the meaning set forth in Section 5(g) of this Agreement.

(p)"Extended Service Plans" has the meaning set forth in Section 4(f)(ii) of this Agreement.

(q)"Fecal Test" means veterinary fecal specimen testing.

(r)"Final Period" has the meaning set forth in Section 5(e)(iv) of this Agreement.

(s)"First Commercial Shipment" means the first commercial shipment of either the Seraspec Platform or the Seraspec Consumables under this Agreement to an unrelated third party in the Territory for end use or consumption, excluding shipments, transfers or dispositions of the Seraspec Platform or Seraspec Consumables without consideration for (i) charitable or promotional purposes; (ii) for preclinical or clinical validation studies; (iii) for test marketing or pre-launch field testing with veterinarians or other potential customers; or (iv) for use in any tests or studies reasonably necessary to comply with applicable laws, regulations or requests from any regulatory authorities.

(t)"First Milestone Shares" has the meaning set forth in Section 5(b) of this Agreement.

(u)"First Tier Customer Support" means selling, installation, user training, software use support, lab support, interface questions, operation of equipment, billing, collections and similar activities relating primarily to the customer.

(v)"GAAP" means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied.

(w)"Grace Period" has the meaning set forth in Section 5(h) of this Agreement.

(x)"Initial Payment" has the meaning set forth in Section 5(a) of this Agreement.

(y)"Initial Period" has the meaning set forth in Section 5(e)(i) of this Agreement.

(z)"Initial Shares" has the meaning set forth in Section 5(a) of this Agreement.

(aa)"Initial Tests" means the Urine Test and the Fecal Test.

4

(bb)"Initial Warranty Period" has the meaning set forth in Section 4(f)(i) of this Agreement.

(cc)"Intellectual Property" means any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (i) issued patents and patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations of any of the foregoing, and other governmental authority-issued indicia of invention ownership (including certificates of invention, petty patents, and patent utility models); (ii) trademarks, service marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing; (iii) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing; (iv) trade secrets, know-how, inventions (whether or not patentable), discoveries, improvements, technology, business and technical information, databases, data compilations and collections, tools, methods, processes, techniques, and other confidential and proprietary information and all rights therein; and (v) all other intellectual or industrial property and proprietary rights.

(dd)"Joint Intellectual Property" has the meaning set forth in Section 7(a)(ii) of this Agreement.

(ee)"Joint Patents" has the meaning set forth in Section 7(b) of this Agreement.

(ff)"Know-How" means any and all technical information, trade secrets, formulas, prototypes, specifications, directions, instructions, test protocols, procedures, results, studies, analyses, raw material sources, data, manufacturing data, formulation or production technology, conceptions, ideas, innovations, discoveries, inventions, processes, methods, materials, machines, devices, formulae, equipment, enhancements, modifications, technological developments, techniques, systems, tools, designs, drawings, plans, software, documentation, data, programs and other knowledge, information, skills and materials

(gg)"License Fees" has the meaning set forth in Section 5(e) of this Agreement.

(hh)"Licensed Know-How" means any and all Know-How that is controlled by Seraph and necessary for the commercialization, use, practice, marketing, sale and distribution of the Product.

(ii)"Licensed Patents" means the patents and patent applications listed on Exhibit A, attached hereto, together with all patents that issue therefrom, and all continuations, continuations-in-part, divisionals, extensions, substitutions, re-issues, re-examinations, and renewals of any of the foregoing.

(jj)"Milestone Payments" has the meaning set forth in Section 5(b) of this Agreement.

(kk)"Minimum Performance Level" has the meaning set forth in Section 6(b) of this Agreement.

5

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(ll)"Non-Bankrupt Party" has the meaning set forth in Section 11(f) of this Agreement.

(mm)"Offer" has the meaning set forth in Section 2(f) of this Agreement.

(nn)"Party" means each of Seraph or Zomedica, and "Parties" means Seraph and Zomedica collectively.

(oo)"Patent Proceedings" means any opposition, re-issue, and re-examination, and any contested case, including inter-partes review, post-grant review, interference, derivation or similar proceedings.

(pp)"Pathogen-Specific Data and Documentation" means data and documentation produced in the course of the Parties' activities under this Agreement relating to: (i) pathogen specific spectral signatures in isolation; and (ii) pathogen specific spectral signatures in confounded sample.

(qq)"Person" means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

(rr)"Post Term Period" has the meaning set forth in Section 11(g).

(ss)"Product" has the meaning set forth in the Background Section of this Agreement.

(tt)"Production Unit" means a Seraspec Platform with applicable UL (or other) certification as appropriate or required by applicable laws for use or sale to companion animal veterinarians to validate the proficiency of production manufacturing capabilities.

(uu)"Project Intellectual Property" has the meaning set forth in Section 7(a)(iii) of this Agreement.

(vv)"Purchase Order" has the meaning set forth in Section 4(d)(ii) of this Agreement.

(ww)"Quarterly Forecast" has the meaning set forth in Section 4(d)(i) of this Agreement.

(xx)[*]

(yy)"Sales Forecast" has the meaning set forth in Section 6(a) of this Agreement.

6

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(zz)"Second Milestone Shares" has the meaning set forth in Section 5(b) of this Agreement.

(aaa)"Second Period" has the meaning set forth in Section 5(e)(ii) of this Agreement.

(bbb)"Second Tier Customer Support" means addressing technical questions that were not able to be addressed by Zomedica in First Tier Customer Support, product warranty, hardware calibration and similar activities relating primarily to the Seraspec Technology and not included in First Tier Customer Support.

(ccc)"Seraspec Consumables" has the meaning set forth in the Background Section of this Agreement.

(ddd)"Seraspec Platform" has the meaning set forth in the Background Section of this Agreement.

(eee)"Seraspec Technology" means the Seraspec Platform, the Seraspec Consumables, Licensed Patents and the Licensed Know-How. In the interest of clarity, except to the extent such technology is Joint Intellectual Property, the Seraspec Technology includes (i) methods for detecting pathogens using Ramen-based spectroscopic analysis; and (ii) any spectral signatures which are developed under this Agreement.

(fff)[*]

(ggg)"Supply Interruption" has the meaning set forth in Section 6(c).

(hhh)"Supply Price" has the meaning set forth in Section 4(c).

(iii)"Statement of Work" means a document executed by the Parties establishing the Parties' specific duties and responsibilities, and associated deliverables, timelines and milestones, with respect to the development and validation of the Product for use in the Zomedica Field of Use.

(jjj)"Term" has the meaning set forth in Section 11(a) of this Agreement.

(kkk)"Territory" means the entire world.

(lll)"Third Milestone Shares" has the meaning set forth in Section 5(b) of this Agreement.

(mmm)"Third Period" has the meaning set forth in Section 5(e)(iii) of this Agreement.

(nnn)"Urine Test" means veterinary urine specimen testing.

(ooo)"Veterinary Market" means the practice of veterinary medicine for the health and wellbeing of pets and other animals. In the interest of clarity, the Veterinary Market does not include (i) food safety or animal product or byproduct applications; (ii) animal import/export control applications; or (iii) any human health applications.

7

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(ppp)"Veterinary-Specific Data and Documentation" means data and documentation produced in the course of the Parties' activities under this Agreement relating to the following items: (i) veterinary clinical validation of Seraspec® results from third party laboratories; (ii) veterinary clinical validation gold standard reference laboratory diagnostic results; (iii) veterinary clinical validation veterinary personal health information for patients; and (iv) veterinary clinical validation reports.

(qqq)"Warehousing Location" means for the period of [*] following the First Commercial Shipment, the manufacturer's onsite warehouse, and for all periods thereafter, a warehouse selected by Zomedica.

(rrr)"WSU License Agreement" has the meaning set forth in Section 2(b) of this Agreement.

(sss)"Zomedica Field of Use" means the following applications within the Veterinary Market: (i) the Urine Test; (ii) the Fecal Test; [*].

(ttt)"Zomedica Gross Profit" means with respect to any Statement of Work, an amount equal to the Zomedica Net Sales of the Seraspec Platforms and Seraspec Consumables under such Statement of Work, less the total Supply Price for the Seraspec Platforms and Seraspec Consumables under such Statement of Work. Notwithstanding the foregoing, Zomedica Gross Profits shall not be deemed to be less than zero (i.e., in the event Zomedica sells any Seraspec Platform or Seraspec Consumable at a loss to Zomedica, the Zomedica Gross Profits attributable to such sale will be deemed to be zero).

(lll)            "Zomedica Net Sales" means the gross amount invoiced for sales or other dispositions of the Seraspec Platforms and Seraspec Consumables by Zomedica, less the following deductions actually incurred, allowed, paid, accrued or otherwise specifically allocated to the Seraspec Platforms and Seraspec Consumables by Zomedica, all in compliance with GAAP, consistently applied by Zomedica:

(a)       normal and customary trade discounts, including trade, cash and quantity discounts or rebates credits or refunds, actually allowed or taken;

(b)       credits or allowances actually granted or made for rejection of or return of previously sold Seraspec Platforms and Seraspec Consumables, including recalls, or for retroactive price reductions and billing errors or for stocking allowances;

(c)       other rebates (or credits or other equivalents thereof) actually granted to trade customers;

(d)      reasonable fees paid to wholesalers, distributors, selling agents (excluding sales representatives of Zomedica), in each case with respect to the Seraspec Platforms and Seraspec Consumables;

8

(e)       charges separately invoiced for freight, insurance, transportation, postage and handling;

(f)       bad debts or provision for bad debt deductions actually written off during the applicable accounting period following the applicable accounting standards used by Zomedica; and

(g)       taxes, custom duties or other governmental charges (including any tax, such as a value added or similar tax or government charge, but excluding what is commonly known as income tax) levied on or measured by the billing amount for Seraspec Platforms and Seraspec Consumables, as adjusted for rebates and refunds.

2.License.

(a)License Grant. Subject to the terms and conditions set forth in this Agreement, Seraph hereby grants to Zomedica during the Term and Post Term Period, an exclusive (other than during the Post Term Period or as otherwise expressly set forth herein) license to the Seraspec Technology, with the right to sublicense solely as provided in Section 2(c), to use, practice, commercialize, market, sell and distribute the Product for use in the Zomedica Field of Use in the Territory. Zomedica shall not, and shall not permit any of its Affiliates to, use or practice any Seraspec Technology outside the scope of the license granted to it in this Section 2(a). Seraph hereby expressly retains for itself and others exclusive rights under the Seraspec Technology to manufacture the Seraspec Platform and the Seraspec Consumables.

(b)Wayne State University Sublicense Terms. Certain of the Seraspec Technology is licensed to Seraph by Wayne State University ("WSU") pursuant to that certain License Agreement between Seraph and WSU dated July 2, 2015, as amended (the "WSU License Agreement"), and the rights granted to Zomedica in this Agreement includes sublicenses under the rights licensed to Seraph under the WSU License Agreement. As such, Zomedica agrees to be bound by those certain provisions from the WSU License Agreement, a copy of which has previously been provided by Seraph.

(c)Sublicensing. Zomedica shall have the right to grant sublicenses of the licenses set forth in Section 2(a), subject to the terms of this Section 2(c) and with the prior written approval of Seraph, which will not be unreasonably withheld or delayed; provided that (i) Zomedica remains fully liable for the performance of its obligations in this Agreement; (ii) Zomedica remains fully liable for the performance of its sublicensees under any sublicense agreement; and (iii) each sublicense agreement is consistent with the terms and conditions of this Agreement. Zomedica shall notify Seraph in writing of every sublicense agreement and amendment thereto within thirty (30) days after their execution.

9

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(d)Seraph Retained Rights. The licenses granted by Seraph under this Agreement are limited to those grants specifically set forth in Sections 2(a), 3(d)(ii) and 7(a)(ii). Nothing in this Agreement will be construed to grant any rights or licenses to any other intellectual property rights of Seraph other than as provided herein. All rights, licenses, benefits and privileges not expressly granted to Zomedica hereunder are reserved by Seraph. For the avoidance of doubt, Seraph shall retain all ownership rights in the Seraspec Technology subject to the terms of this Agreement.

(e)Exclusivity. As partial consideration for the grant of rights set forth in Section 2(a) and provided that Seraph is not in breach of its material obligations under this Agreement, Zomedica agrees that during the Term of this Agreement, it and its Affiliates shall not, in any country in the Territory which the Product has been commercialized, directly or indirectly market, distribute or sell any in-clinic or point of care technology or product that directly competes with the Product actually developed and commercialized by Zomedica hereunder in the Zomedica Field of Use.

(f)Right of First Offer. If at any time during the Term of this Agreement Seraph intends to offer the right to market, distribute or sell the Seraspec Technology for use outside the Zomedica Field of Use but within the Veterinary Market or Seraph intends to engage in a Change in Control, Seraph must first make a written offer to Zomedica to negotiate and enter into a business relationship or Change in Control upon the substantially the same terms that Seraph intends to offer to a third party (the "Offer"). With the Offer, Seraph will provide Zomedica all information available to Seraph with respect to the Offer. Within [*] of Zomedica's receipt of the Offer from Seraph, Zomedica shall notify Seraph that it either accepts the terms of the Offer or that it rejects the Offer. In the case of acceptance of the Offer, the contract for the business relationship or Change in Control shall be closed within [*] following such acceptance, or such other period as the Parties may mutually agree.

3.Development and Validation.

(a)Development Plan. The Parties shall jointly undertake activities to develop and validate the Seraspec Technology for use in the Zomedica Field of Use pursuant to the activities set forth in the Statements of Work (the "Development Plan"). Each Statement of Work under this Agreement will be issued in writing and will be effective when signed by an authorized representative of each of the Parties. No Statement of Work may be amended, modified, changed or supplemented except by a writing signed by an authorized representative of each of the Parties. Each Statement of Work will reference and incorporate the terms of this Agreement. The terms and conditions of this Agreement apply to any and all Statements of Work executed by the Parties that reference this Agreement, and all such Statements of Work will be governed by the terms and conditions of this Agreement. The initial Statement of Work, addressing the development and validation activities related to the Initial Tests is attached hereto as Exhibit B. One or more subsequent Statements of Work will address the development and validation activities related to [*], and will be established by the Parties following the Effective Date.

10

(b)Efforts. Each Party will use its Commercially Reasonable Efforts, including devoting sufficient time, attention and qualified personnel, to meet the delivery dates for any deliverables and complete other matters agreed to in the Development Plan. The Parties will provide each other with such technical support relating to the development and validation of the Product for use in the Zomedica Field of Use in accordance with the Development Plan as reasonably necessary for the Parties to execute the Development Plan. The Parties acknowledge that in connection with the Development Plan, each of the Parties may need access to certain Confidential Information of the other Party and that such Confidential Information will be subject to the confidentiality provisions set forth in Section 8 hereof. Each Party agrees to notify the other promptly of any factor, occurrence, or event coming to its attention that may have a material negative effect on that Party’s ability to meet the requirements of the Development Plan generally, or that is likely to cause any material delay in the delivery of deliverables. Upon receipt of such notice the parties shall discuss in good faith the responsibility for such delays and determine who shall bear the cost of such delay of failure to meet the requirements of the Development Plan.

(c)Development Costs. Zomedica will be responsible for and bear all Development Costs, and shall compensate Seraph for any of its Development Costs in accordance with the amounts set forth in the applicable Statement of Work. With respect to Development Costs incurred by Seraph under a Statement of Work, Seraph shall invoice Zomedica on a monthly basis for such costs, and Zomedica will pay such invoices within forty-five (45) days of receipt. Zomedica shall promptly notify Seraph if the Development Costs exceed or are reasonably likely to exceed the budgeted costs set forth in the applicable Statement of Work.

(d)Records and Reports.

(i)Each Party shall maintain complete, current and accurate records of all activities undertaken by such Party pursuant to the Development Plan, including without limitation, all data, Know-How and patents resulting from such work, and all Development Costs incurred in connection therewith. The Parties will report the results of the Development Plan to each other informally on a regular basis. In addition, by the end of calendar months December and June of each year, Zomedica shall provide written reports to Seraph on its activities under the Development Plan in a form reasonably acceptable to the Parties, detailing (i) all of the work conducted by Zomedica during the previous six (6) months; (ii) all data, Know-How and patents resulting from such work during the previous six (6) months; and (iii) all Development Costs incurred in connection therewith during the previous six (6) months.

(ii)All rights, title and interest in and to all Development Data and Documentation shall be owned by Seraph. Zomedica hereby assigns all rights, title and interest in and to such Development Data and Documentation to Seraph, and Zomedica shall execute such documents and perform such acts as may be necessary to vest title thereto in Seraph. Seraph shall provide Zomedica a copy of all such Development Data and Documentation, and hereby grants Zomedica a perpetual, irrevocable, royalty-free, worldwide exclusive license to use the Development Data and Documentation, but excluding the Pathogen-Specific Data and Documentation, in the Zomedica Field of Use. Seraph hereby grants Zomedica during the Term and Post Term Period a royalty-free, worldwide exclusive license to use the Pathogen-Specific Data and Documentation in the Zomedica Field of Use. The Development Data and Documentation shall constitute Seraph's Confidential Information, and Seraph shall be deemed to be the Disclosing Party with respect thereto.

11

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(iii)All rights, title and interest in and to all Veterinary-Specific Data and Documentation shall be owned by Zomedica. Seraph hereby assigns all rights, title and interest in and to such Veterinary-Specific Data and Documentation to Zomedica, and Seraph shall execute such documents and perform such acts as may be necessary to vest title thereto in Zomedica. Zomedica shall provide Seraph a copy of all such Veterinary-Specific Data and Documentation, and hereby grants Seraph a perpetual, irrevocable, royalty-free, worldwide exclusive license to use such Veterinary-Specific Data and Documentation outside the Zomedica Field of Use. Veterinary-Specific Data and Documentation shall constitute Zomedica's Confidential Information, and Zomedica shall be deemed to be the Disclosing Party with respect thereto.

4. Commercial Activities.

(a)Distribution Rights. Subject to the terms and conditions set forth in this Agreement, including without limitation the minimum performance objectives set forth in Section 6, Seraph hereby appoints Zomedica as its exclusive (even as to Seraph, and other than during the Post Term Period or otherwise as expressly set forth herein) distributor to market and promote sales of the Product for use in the Zomedica Field of Use in the Territory, and Zomedica hereby accepts such appointment and agrees to act as such distributor. Zomedica may appoint dealers or sub-distributors to distribute, market and sell the Product for use in the Zomedica Field of Use in the Territory.

(b)Manufacture and Supply. Seraph shall manufacture or have manufactured, and shall supply the Seraspec Platforms and Seraspec Consumables to Zomedica and its customers according to the terms and conditions of this Agreement, and on an exclusive basis in the Zomedica Field of Use. Seraph shall at all times maintain and cause any third party manufacturers or suppliers to maintain sufficient capacity to meet the Quarterly Forecast provided by Zomedica. In the interest of clarity, Seraph shall have the exclusive right and obligation to manufacture and package the Seraspec Platforms and Seraspec Consumables for all purposes both inside and outside the Zomedica Field of Use.

(c)Prices.

(i)Zomedica shall purchase the Seraspec Platforms and Seraspec Consumables from Seraph at the following prices (the "Supply Price"):

(1)Zomedica shall purchase the Seraspec Platforms from Seraph at a price equal to the Cost of Purchase for such Seraspec Platform, plus [*]; and

12

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(ii)Zomedica shall purchase the Seraspec Consumables from Seraph at a price equal to the Cost of Purchase for such Seraspec Consumables, plus [*]. During the Term, on a calendar quarter basis, Seraph shall provide Zomedica with an accounting of its Cost of Purchase for the Seraspec Platforms and Seraspec Consumables (broken out by Statement of Work) at the beginning of each calendar quarter, which accounting shall be used in the calculation of the Supply Price for the quarter.

(d)Forecasts; Ordering.

(i)During the Term and the Post Term Period, on a calendar-quarter basis, Zomedica shall submit to Seraph a rolling twelve-month forecast for the purchase of the Seraspec Platform and the Seraspec Consumables (the "Quarterly Forecast"). The Quarterly Forecast shall be non-binding and shall reflect Zomedica's good faith estimates of expected orders of the Seraspec Platform and the Seraspec Consumables. The Quarterly Forecasts are for informational purposes only and do not create any binding obligations on behalf of either Party; provided, however, that Seraph shall not be required to manufacture and sell to Zomedica any quantity of Seraspec Platforms or Seraspec Consumables that is greater than [*] of any Quarterly Forecast for the period covered by such Quarterly Forecast.

(ii)Zomedica shall issue purchase orders containing applicable terms that are consistent with the terms of this Agreement to Seraph ("Purchase Orders"), in written form via e-mail or US mail. By issuing a Purchase Order to Seraph, Zomedica makes an offer to purchase Seraspec Platforms and/or Seraspec Consumables pursuant to the terms and conditions of this Agreement and the Basic Purchase Order Terms contained in such Purchase Order, and on no other terms. For the avoidance of doubt, any variations made to the terms and conditions of this Agreement by Zomedica in any Purchase Order are void and have no effect. Upon receipt of the Purchase Order, Seraph shall issue Zomedica an invoice setting forth the Supply Price for the Seraspec Platforms and Seraspec Consumables subject to such Purchase Order. Zomedica shall pay each invoice within [*] following delivery of the Seraspec Platforms and/or Seraspec Consumables and receipt of an invoice.

(iii)Seraph shall deliver the Seraspec Platforms and Seraspec Consumables specified in each Purchase Order, EX Works (Incoterms 2010) Warehousing Location within [*] from Seraph's receipt of the Purchase Order; provided, however, that the quantity of Seraspec Platforms and Seraspec Consumables specified in such Purchase Agreement are not greater than [*] of the Quarterly Forecast. In all other cases, Seraph shall deliver the Seraspec Platforms and Seraspec Consumables as promptly as reasonably possible following Seraph's receipt of the Purchase Order. In the interest of clarity, Zomedica shall be responsible for shipment of all Seraspec Platforms and Seraspec Consumables from the Warehousing Location to the end customers at its own expense.

(iv)Until the first anniversary of the First Commercial Shipment, all costs associated with the warehousing of the Seraspec Platforms and Seraspec Consumables at the Warehousing Location shall be borne by Seraph. Following the first anniversary of the First Commercial Shipment, all costs associated with the warehousing of the Seraspec Platforms and Seraspec Consumables at the Warehousing Location shall be borne by Zomedica.

13

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(e)Quality Audit.

(i)                 Seraph shall use Commercially Reasonable Efforts to ensure the quality of the Seraspec Platforms and Seraspec Consumables prior to shipment. Seraph represents and warrants that all Seraspec Platforms and Seraspec Consumables shipped under this Agreement shall be manufactured to quality standards at least as exacting as those required for Seraph's sales into markets outside the Zomedica Field of Use and in compliance with all applicable laws, rules and regulations; provided, however, that Zomedica shall inform Seraph of any applicable laws, rules and regulations that are specific to the Zomedica Field of Use. In addition, the Parties shall mutually agree upon specific manufacturing quality requirements on an as-needed basis for specific regions in the Territory, or as required by applicable regulatory or market requirements in the Zomedica Field of Use.

(ii)               Seraph or its manufacturer shall maintain inspection and other relevant manufacturing records with respect to the Seraspec Platforms and Seraspec Consumables ordered and shipped under this Agreement. The relevant types of records to be maintained shall be listed in Exhibit F, as amended from time to time. Seraph shall provide, or shall cause its manufacturer to provide, Zomedica with such inspection reports and records upon Zomedica's request. Zomedica shall have the right to carry out, not more than once per calendar year, and upon reasonable prior notice quality, capacity and manufacturing audits of Seraph and its manufacturers used for the manufacture of the Seraspec Platforms and Seraspec Consumables subject to this Agreement.

(f)                Warranty.

(i)Seraph warrants to Zomedica and its end customers that, for a period of [*] following Zomedica's acceptance of a Seraspec Platform (the "Initial Warranty Period"), that the Seraspec Platform will be free from material defects in material and workmanship. The limited warranty in this Section 4(f) does not apply where the Seraspec Platform has:

(1)been subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper installation, improper storage, improper handling, abnormal physical stress, abnormal environmental conditions or use contrary to any instructions issued by Seraph;

14

(2)been reconstructed, repaired or altered by persons other than Seraph or its authorized representatives; or

(3)been used with any third-party product, hardware or product that has not been previously approved in writing by Seraph.

(ii)Zomedica and Seraph may mutually agree to offer extended service plans for the Seraspec Platforms beyond the Initial Warranty Period to Zomedica customers for purchase (the "Extended Service Plans"). The Extended Service Plans will include warranty, repair and customer service levels substantially similar to those afforded during the Initial Warranty Period. At least 45 days prior to the anticipated date of First Commercial Shipment, the parties will negotiate in good faith the terms under which Seraph shall sell to Zomedica the Extended Service Plan, in accordance with the Customer Service Requirements and Warranty Guidelines attached hereto as Exhibit E, which Zomedica can then resell to Zomedica’s customers at such price determined by Zomedica in its sole and absolute discretion. In the event such Extended Service Plans are instituted and purchased by a Zomedica customer, the provisions of this Section 4(f) shall apply to any Seraspec Platforms subject to such Extended Service Plans.

(iii)During the Initial Warranty Period, or during term of the Extended Service Plan, if applicable, and after conducting all applicable First Tier Customer Support related to such alleged claim or defect, Zomedica shall promptly notify Seraph, in writing, of any alleged claim or defect in the Seraspec Platform. Seraph shall then provide all applicable Second Tier Customer Support related to such alleged claim or defect.

(iv)In the event Seraph is not able to rectify the alleged claim or defect through the Second Tier Customer Support, Seraph shall ship, at its expense and risk of loss, a new or refurbished Seraspec Platform directly to such customer, and the customer shall, at its expense and risk of loss, send such allegedly defective Seraspec Platform to Seraph's facility.

(v)Neither Zomedica nor its customers have any right to return for repair, replacement, credit or refund any Seraspec Platforms except as set forth in this Section 4(f). In no event shall Zomedica reconstruct, repair, alter or replace any Seraspec Platforms, in whole or in part, either itself or by or through any third party.

(vi)EXCEPT FOR THE WARRANTY SET FORTH IN THIS SECTION 4(F), SERAPH MAKES NO WARRANTY WHATSOEVER WITH RESPECT TO THE SERASPEC PLATFORMS OR SERASPEC CONSUMABLES, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY; (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTY OF TITLE; OR (D) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY; WHETHER EXPRESS OR IMPLIED BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE. THIS SECTION SETS FORTH ZOMEDICA'S AND ITS CUSTOMERS' SOLE REMEDY AND SERAPH'S ENTIRE LIABILITY FOR ANY BREACH OF THE LIMITED WARRANTY SET FORTH IN SECTION 4(F).

15

(g)               Branding. Zomedica shall provide branding for the Seraspec Platforms and Seraspec Consumables to be provided under this Agreement and shall bear all costs related to Zomedica branding of the Product. The Seraspec Platforms and Seraspec Consumables will also display Seraph's brand, and Zomedica will not alter or remove such branding.

(h)               Marketing, Sales & Customer Support.

(i)Zomedica shall be solely responsible for commercialization and marketing of the Seraspec Technology in the Zomedica Field of Use, and in furtherance thereof, shall be solely responsible for providing First-Tier Customer Support related to the Seraspec Technology in the Zomedica Field of Use.

(ii)Seraph shall be solely responsible for all Second-Tier Customer Support related to the Seraspec Technology in the Zomedica Field of Use.

(iii)The Parties shall share responsibility for post-market surveillance of the Seraspec Technology in the Zomedica Field of Use, including without limitation gathering call data, repair and replacement data, customer feedback and other relevant information in the course of providing the First-Tier Customer Support and the Second-Tier Customer Support. Each Party will share with the other Party all such information and data gathered from such surveillance.

(i)                 Regulatory. Zomedica shall, at its own expense, be solely responsible for all regulatory activities, including without limitation, any required regulatory approvals, if any, related to the use of the Seraspec Technology solely within the Zomedica Field of Use, or related to Zomedica's activities under this Agreement. Seraph shall, at its own expense, be solely responsible for all regulatory activities related to the manufacture and use of the Seraspec Technology that relate to uses both inside and outside the Zomedica Field of Use.

5. Compensation.

(a)Upfront Payment. As partial consideration for the rights granted to Zomedica herein, Zomedica shall pay to Seraph, on the Effective Date, an initial payment of One Million Seven Hundred Fifty Thousand Dollars ($1,750,000) (the "Initial Payment"). The Initial Payment shall be paid as follows: (i) Five Hundred Thousand Dollars ($500,000) in cash in immediately available funds; and (ii) the issuance, in accordance with Section 5(c), of that number of shares of Zomedica's common stock determined by dividing One Million Two Hundred Fifty Thousand Dollars ($1,250,000) by the volume-weighted average price of Zomedica's shares of common stock on the NYSE American exchange over the ten (10) trading days prior to the Effective Date (the "Initial Shares").

16

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(b)Milestone Payments. As partial consideration for the rights granted to Zomedica herein, Zomedica shall make the following payments to Seraph upon the achievement of the following milestone events (the "Milestone Payments"):

Milestone Event	Milestone Amount	Form of Payment
[*]	$500,000	Cash in immediately available funds
[*]	$500,000	Cash in immediately available funds
[*]	$2,000,000	The issuance in accordance with Section 5(c) of that number of shares of Zomedica common stock determined by dividing $2,000,000 by the volume-weighted average price of Zomedica stock on the NYSE American exchange over the ten (10) trading days prior to achievement of the milestone event (the "First Milestone Shares").
[*]	$1,250,000	Cash in immediately available funds
[*]	$750,000	The issuance in accordance with Section 5(c) of that number of shares of Zomedica common stock determined by dividing $750,000 by the volume-weighted average price of Zomedica stock on the NYSE American exchange over the ten (10) trading days prior to achievement of the milestone event (the "Second Milestone Shares").
[*]	$1,250,000	Cash in immediately available funds
[*]	$750,000	The issuance in accordance with Section 5(c) of that number of shares of Zomedica common stock determined by dividing $750,000 by the volume-weighted average price of Zomedica stock on the NYSE American exchange over the ten (10) trading days prior to achievement of the milestone event (the "Third Milestone Shares").

17

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(c)Registration of Securities. The securities to be issued pursuant to this Agreement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. Notwithstanding the foregoing, Zomedica shall file a registration statement to register the securities issued pursuant to this Agreement for resale in the United States, including the Initial Shares, the First Milestone Shares, the Second Milestone Shares and the Third Milestone Shares, in the time and manner as set forth in Exhibit D attached hereto and incorporated herein by this reference and perform certain other covenants as set forth in such Exhibit D.

(d)Calculation and Payment of License Fees. Following the First Commercial Shipment, on a calendar quarter basis, Zomedica shall provide Seraph with an accounting of the Zomedica Gross Profit for the Seraspec Platforms and Seraspec Consumables (broken out by test) at the end of each calendar quarter, which accounting shall be used in the calculation of the License Fee for such quarter. Zomedica shall pay Seraph the License Fees within [*] following the end of the calendar quarter in which such License Fees were earned.

(e)License Fees. As partial consideration for the rights granted to Zomedica herein, Zomedica shall pay Seraph the license fees identified in this Section 5(e) (the "License Fees") with respect to each Statement of Work.

(i)For the first [*] months following the First Commercial Shipment under such Statement of Work (the "Initial Period"), Zomedica shall pay Seraph a License Fee equal to [*] of the Zomedica Gross Profit on the sale of the Seraspec Consumables and Seraspec Platforms under such Statement of Work. The following sections notwithstanding, the Initial Period shall last for no less than 12 months;

(ii)Beginning in the [*] month following the First Commercial Shipment under such Statement of Work and until the beginning of the Third Period (the "Second Period"), Zomedica shall pay Seraph a License Fee equal to [*] of the Zomedica Gross Profit on the sale of the Seraspec Consumables and Seraspec Platforms under such Statement of Work;

(iii)Beginning in the first month after Zomedica has recouped the entirety of the Development Costs associated with such Statement of Work (as contemplated in Section 5(g)) and until the beginning of the Final Period (the "Third Period") but not less than [*] months following the First Commercial Shipment, Zomedica shall pay Seraph a License Fee equal to [*] of the Zomedica Gross Profit on the sale of the Seraspec Consumables and Seraspec Platforms under such Statement of Work; and

18

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(iv)Beginning in the first month following the [*] year anniversary of the First Commercial Shipment under each Statement of Work (the "Final Period"), Zomedica shall pay Seraph a License Fee equal to [*] of the Zomedica Gross Profit on the sale of the Seraspec Consumables and Seraspec Platforms under such Statement of Work.

(f)Sublicense Fees under WSU Agreement. Seraph shall be responsible for paying the Sublicense Fees (as defined in the WSU Agreement) owed to WSU under the WSU Agreement during the Term of the WSU Agreement.

(g)Zomedica Recovery of Development Costs. The graduated schedule of License Fees set forth in Section 5(e) is intended to allow Zomedica to recover its Development Costs relating to each Statement of Work. During the Initial Period and the Second Period, any Zomedica Gross Profit retained by Zomedica, which is in excess of the amount would be retained by Zomedica if the License Fee from the Final Period were applied to the Zomedica Gross Profit during that period, (the "Excess Gross Profit") shall be applied toward recovery of the Development Costs attributable to such Statement of Work.

(i)By way of example, and not limitation, with respect to any specific Statement of Work, if Zomedica Gross Profit during the Initial Period were $2,000,000, the application of such Zomedica Gross Profit to the recovery of the Development Costs shall be calculated as follows:

Zomedica Gross Profit actually retained by Zomedica during the Initial Period = ($2,000,000 * [*]%) = [*]

Zomedica Gross Profit that would be retained by Zomedica if License Fees from Final Period were applied = ($2,000,000 * [*]%) = [*]

Excess Gross Profit applied to recoupment of Development Costs = [*]

(ii)In the interest of clarity, the Initial Payment and the Milestone Payments are not subject to any recovery by Zomedica of the Development Costs and the application of Excess Gross Profit toward the recovery of Development Costs shall be specific to each Statement of Work (i.e., Zomedica Gross Profit relating to the sale of Seraspec Consumables for the Initial Tests will not be subject to cost recovery by Zomedica of Development Costs attributable to subsequent Statements of Work).

(h)Licensee Fee Reduction for Supply Interruption. In the event of a Supply Interruption, as that term is defined in Section 6(c), Seraph shall have 60 days to cure the Supply Interruption without penalty by completing final delivery of all then-ordered Products according to Section 4(d)(iii) (the "Grace Period"). If a Supply Interruption occurs and is not wholly cured and all such Products delivered within 60 days, then for any Seraspec Platforms or Seraspec Consumables which were the subject of the Supply Interruption, and which have not been delivered within the 60 days, the License Fees payable to Seraph under Section 5(e) with respect to those Seraspec Platform and Seraspec Consumable units will be reduced by [*]. Any additional Zomedica Gross Profit retained by Zomedica as a result of Supply Interruptions that extend beyond the Grace Period shall not apply toward the recovery of Zomedica’s Development Costs under Section 5(g).

19

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(i)True-Up. Within ninety (90) days of the end of each year, Zomedica shall provide an accounting of Zomedica Net Sales for that year, inclusive of any delayed or volume based rebates not reflected on the date of sale. If the License Fees which would be payable under this end-year accounting differ from the Licensee Fees actually paid during that year, the Party which has benefited from any such discrepancy shall remit the cash amount of the License Fee discrepancy to the other Party within ninety (90) days.

(j)Records and Audit. Each Party shall maintain the usual books of account and records accounting for its activities under this Agreement. During the Term and the Post Term Period and for one (1) year thereafter, upon reasonable notice and at the sole expense of the requesting party, but no more than once per calendar year, such books and records shall be open to inspection and copying by an independent certified public account acceptable to the other party, for the purpose of verifying the accuracy of the amounts paid under this Agreement. In the event that such review shows an error of five percent (5%) or more in either Party's favor, the difference, together with interest on past due amounts at a rate of [*] per annum, and reimbursement for the expense of such audit, if applicable, shall be paid to the deficient Party.

6. Performance Metrics; Competitors; Claw-Back of Rights.

(a)Zomedica shall use its Commercially Reasonable Efforts to market, distribute and sell the Seraspec Technology in the Zomedica Field of Use, including without limitation, timely invoicing customers and collecting revenues for such sales, and purchasing Product in accordance with the following sales forecast (the "Sales Forecast"):

	Months [*] following First Commercial Shipment	Months [*] following First Commercial Shipment	Months [*] following First Commercial Shipment
Seraspec Platform	[*]	[*]	[*]
Seraspec Consumables	[*]	[*]	[*]

20

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(b)In the event that Zomedica fails to purchase at least [*]% of the Sales Forecast for any period referenced in the table above (the "Minimum Performance Level"), and provided that Seraph is not in default of any of its material commercial obligations under this Agreement, including but not limited to the obligation to supply such quantities of Seraspec Platform and Seraspec Consumables set forth in the Purchase Orders, [*]

(i)[*]

(ii)[*]

(c)In the event that Seraph materially fails to meet its supply obligations – including those enumerated in Section 4(d)(iii) – at any time when the Minimum Performance Levels apply (a "Supply Interruption"), then in such case the Minimum Performance Levels shall be suspended during the Supply Interruption and for an additional period equal to twice the length of the Supply Interruption (the "Interruption Period"). To that end, both the period referenced in the table in Section 6(a) during which such Supply Interruption occurred and the Term shall each be extended by an amount of time commensurate with the Interruption Period.

By way of example, and not limitation, if a Supply Interruption lasts 1 month, the Interruption Period would be equal to 3 months (1 month plus 2 months (i.e., twice the length of the Supply Interruption)) and the Period in which the Supply Interruption occurred and the Term would each be extended by 3 months. Consequently Zomedica would have 3 additional months to meet the Minimum Performance Level for the relevant Period, and the Term would be extended to account for such additional 3 months (e.g., from 7 years to 7 years and 3 months, assuming this was the first Supply Interruption).

(d)Notwithstanding the foregoing, in the event that Seraph and Zomedica mutually agree that a competitive Raman spectroscopy solution is brought to market in the Zomedica Field of Use, and the pricing of the Seraspec Technology to Zomedica customers must be adjusted as a direct response, the Minimum Performance Level shall be [*]% of the Sales Forecast.

(e)In the event that Zomedica fails to have a reasonable commercial sales force in place at least [*] prior to the anticipated First Commercial Shipment, Seraph may, in its sole discretion, [*].

(f)The Parties understand and agree that the forecasts herein are based on launch of a commercial Product that is capable of detecting the pathogens identified in the first Statement of Work to this agreement. If, during the course of the development activities outlined in the Statement of Work, Zomedica determines that the first commercial Product will differ in its capabilities from these original expectations, the Parties agree to meet in good faith and amend the forecasts to account for these differences.

7. Intellectual Property.

(a)Ownership.

(i)The Parties hereby acknowledge and agree that each Party retains all right, title and interest in and to the Intellectual Property of such Party owned or independently developed by such Party prior to the Effective Date. Except as expressly set forth herein, neither Party grants to the other Party pursuant to this Agreement, any rights or licenses under the Intellectual Property owned by such Party or its Affiliates.

21

(ii)All Intellectual Property that is jointly made, discovered, conceived, reduced to practice or developed by Seraph and Zomedica under this Agreement and which relates only to veterinary patient care ("Joint Intellectual Property") shall be jointly owned by Seraph and Zomedica. Seraph hereby grants to Zomedica an irrevocable royalty-free, worldwide exclusive right and license to Seraph's interest in such Joint Intellectual Property to use such Joint Intellectual Property in the Zomedica Field of Use. Zomedica hereby grants to Seraph an irrevocable, royalty-free, worldwide exclusive right and license to Zomedica's interest in such Joint Intellectual Property to use such Joint Intellectual Property for all purposes outside the Zomedica Field of Use. The licenses granted in this Section 7(a)(ii) shall survive the termination or expiration of this Agreement.

(iii)The Parties hereby agree that all Intellectual Property made, discovered, conceived, reduced to practice or developed under this Agreement that is not Joint Intellectual Property ("Project Intellectual Property") shall be owned solely by Seraph. Zomedica agrees to assign and hereby does assign all of its right, title and interest in and to all Project Intellectual Property to Seraph. Any such Intellectual Property shall be considered Seraspec Technology and shall be subject to the license granted to Zomedica under this Agreement. The Parties agree to execute all necessary documents in a reasonable and prompt manner to effectuate the foregoing assignment.

(b)Prosecution and Maintenance of Joint Intellectual Property.

(i)Zomedica shall have the exclusive right and (subject to Zomedica's election not to file, prosecute, or maintain or conduct Patent Proceedings pursuant to this Section 7(b)) at Zomedica's cost, obligation to diligently file, prosecute and maintain patents relating to Joint Intellectual Property ("Joint Patents"), and to conduct any Patent Proceedings with respect thereto. Zomedica may elect not to file, prosecute or maintain the Joint Patents, or conduct any Patent Proceedings with respect thereto, and may cease prosecution or maintenance thereof or any Patent Proceeding with respect thereto, in each case on a country-by-country basis, by providing Seraph with advance written notice. If Zomedica so elects by advance written notice, Seraph, at its sole discretion and expense, may take such actions to the extent Seraph so elects, but Seraph shall notify Zomedica in writing at least ten (10) days before taking any such action. If Seraph elects to take such actions as permitted pursuant to this Section 7(b), Zomedica shall execute such documents and perform such acts as may be reasonably necessary to allow Seraph to file, initiate or continue such prosecution or maintenance in any such country.

(ii)               During the Term:

(1)               Zomedica shall keep Seraph advised on at least a quarterly basis of the status of all actual and prospective Joint Patents;

22

(2)               Zomedica shall provide advance copies of any material papers related to the filing, prosecution and maintenance of Joint Patents;

(3)               Zomedica shall promptly, but in any case within thirty (30) days of learning of such event, give notice to Seraph of the grant, lapse, revocation, surrender, invalidation or abandonment of any Joint Patents; and

(4)               Zomedica shall solicit Seraph's advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, provided Zomedica shall not have any obligation with respect to Seraph's comments related thereto.

(iii)             If Seraph notifies Zomedica that it wishes Zomedica to file and prosecute a Joint Patent, or to conduct any Patent Proceeding with respect thereto, Zomedica shall undertake such activities in such countries and/or conduct such proceedings at Seraph's expense.

(c)                Interference, Opposition, Re-examination and Re-issue.

(i)                 During the Term, Zomedica shall promptly, but in any case within thirty (30) days of learning of such event, inform Seraph of any request for or declaration of any interference, opposition or re-examination relating to a Joint Patent. Zomedica shall provide Seraph with written notice as soon as practicable prior to initiating any re-examination, interference or re-issue proceeding relating to the Joint Patents. The Parties shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. Seraph shall have the right to review any submission to be made in connection with such proceeding.

(ii)               In connection with any Patent Proceeding relating to Joint Patents, the Parties shall cooperate fully and shall provide each other with any information or assistance that either may reasonably request, each at its own expense. Zomedica shall keep Seraph informed of developments in any such action or proceeding, including, to the extent permissible by law, consultation regarding any settlement, the status of any settlement negotiations and the terms of any offer related thereto.

(iii)             Zomedica shall be responsible for any out-of-pocket expenses related to any Patent Proceeding with respect to any Joint Patent.

(d)Enforcement. Each Party shall promptly advise the other in writing of any known acts of actual or potential infringement of the Seraspec Technology in the Zomedica Field of Use. Zomedica shall use Commercially Reasonable Efforts to identify actual or potential infringing activities within the Zomedica Field of Use. Zomedica shall use Commercially Reasonable Efforts to cause any infringing party to cease and desist infringing activities at Zomedica's sole expense; provided that Zomedica shall not initiate or defend any formal action, except as contemplated by Section 7(d)(ii).

23

(i)                 Enforcement by Seraph.

(1)To the extent that an issued, unexpired claim in the Licensed Patents covers the Seraspec Technology, Seraph has the first option to police the Licensed Patents against infringement by other parties in the Zomedica Field of Use, but Seraph shall notify Zomedica in writing at least ten (10) days before filing any suit. The right to police includes defending any action for declaratory judgment of non-infringement or invalidity; and prosecuting, defending or settling all infringement and declaratory judgment actions at its expense and through counsel of its selection. Zomedica shall provide reasonable assistance to Seraph with respect to such actions, and Seraph shall reimburse Zomedica for the reasonable out of pocket expenses incurred in connection with any such assistance rendered at Seraph's request or reasonably required by Seraph. Zomedica retains the right to participate, with counsel of its own choosing and at its own expense, in any action under this Section 7(d)(i).

(2)Seraph shall defend, indemnify and hold harmless Zomedica with respect to any counterclaims asserted by an alleged infringer reasonably related to the enforcement of the Licensed Patents under this Section 7(d)(i), including, without limitation, antitrust counterclaims; provided, however that Seraph shall have no obligation to defend, indemnify or hold Zomedica harmless with respect to any such counterclaim that arises from Zomedica's gross negligence or willful misconduct. If Seraph undertakes to enforce and/or defend the Licensed Patents by litigation, Seraph shall pay all costs thereof and shall be entitled to all damages recovered in any such litigation; provided, however, that if Zomedica exercises its right to participate in such action with counsel of its own choosing and at its own expense, the recovery of any such action shall be shared by the Parties proportionately, relative to their respective costs and expenses with respect to the action.

(3)For any action relating to any infringement of Licensed Patents under this Section 7(d)(i), if Seraph is unable to initiate or prosecute such action solely in its own name, Zomedica shall, at Seraph's expense, join such action voluntarily and shall execute all documents necessary for Seraph to initiate litigation to prosecute and maintain such action. In connection with any action, the Parties shall cooperate fully and shall provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other informed of developments in any action or proceeding, including, to the extent permissible by law, the consultation and approval of any settlement negotiations and the terms of any offer related thereto.

(ii)Enforcement by Zomedica. If Zomedica notifies Seraph of a material infringement in the Zomedica Field of Use, and Seraph fails to take action to abate any such infringement within ninety (90) days of a request by Zomedica to do so (or within a shorter period if required to preserve the legal rights of Zomedica under any applicable laws) then Zomedica has the right to take such action (including, without limitation, prosecution of a suit) and Seraph shall use reasonable efforts to cooperate in such action, including without limitation, being named in such action if necessary for the purposes of standing. If Zomedica undertakes to enforce and/or defend the Licensed Patents by litigation, Zomedica shall pay all costs thereof (including reimbursement of any costs to Seraph for its participation in the action) and shall be entitled to all damages recovered in any such litigation; provided, however, that if Seraph exercises its right to participate in such action with counsel of its own choosing and at its own expense, the recovery of any such action shall be shared by the Parties proportionately, relative to their respective costs and expenses with respect to the action. With respect to any action by Zomedica under this Section 7(d)(ii), Zomedica shall act in good faith to preserve the validity of and Seraph's right, title and interest in and to the Licensed Patents, shall keep Seraph advised as to the status of the action, and shall not enter into a settlement without first allowing Seraph the option of either approving the settlement or continuing the lawsuit at Seraph's expense and for Seraph's benefit (after payment to Zomedica of its out-of-pocket and expenses of the action incurred after the settlement is rejected).

24

8.Confidential Treatment. The Parties agree to maintain in confidence and use the Confidential Information of each other Party solely for the purpose of conducting the activities contemplated by this Agreement. Neither Party may make any copies of the Confidential Information (whether in tangible, intangible or electronic format) of the other Party except to the extent required in connection with its activities under this Agreement. The Receiving Party may not (a) use the Confidential Information of the Disclosing Party for any commercial or non-commercial purpose or gain, other than for the purposes set forth in this Agreement, (b) reverse engineer any of the Confidential Information of the other Party, or (c) disclose the Confidential Information of the other Party except to the extent reasonably necessary or appropriate to fulfill the receiving Party’s obligations or exercise its rights under this Agreement, under circumstances that reasonably ensure the confidentiality thereof. Nothing contained in this Section 8 shall prevent either Party from disclosing any Confidential Information of the other Party to the extent reasonably necessary to comply with applicable laws, regulations or orders (including to the extent required for the submission of regulatory filings related to the activities contemplated by this Agreement); provided that if a Party is required by law to make any such disclosure of the other Party’s Confidential Information other than pursuant to a confidentiality agreement, it will, to the extent legally permissible, give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such Confidential Information.

9.Representations and Warranties.

(a)Each Party represents and warrants that, as of the Effective Date:

(i)it has the corporate and legal right, authority and power to enter into this Agreement, and to extend the rights granted to the other Party in this Agreement;

(ii)it has taken all necessary action to authorize the execution, delivery and performance of this Agreement;

25

(iii)the performance of such Party under this Agreement will not conflict with its charter documents or result in a breach of any agreements, contracts or other arrangements to which it is a party; and

(iv)neither Party nor any of such Party’s Affiliates has been disbarred or is subject to debarment and neither Party nor any of such Party’s Affiliates shall use in any capacity in connection with the services to be performed under this agreement any person who has been debarred pursuant to Section 306 of the Food Drug and Cosmetic Act (21 U.S.C. 335a) (the "Act") or who is subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately if any person who is performing services on behalf of such Party under this Agreement is debarred or is the subject of a conviction described in Section 306 of the Act or if any action, suit, claim, investigation or legal or administrative proceeding or to the knowledge of such Party is threatened relating to the debarment or conviction of such Party or any person performing services on behalf of such Party under this Agreement.

(b)Seraph Representations, Warranties and Covenants. In addition to the representations and warranties made by Seraph above and elsewhere in this Agreement, Seraph hereby represents, warrants, and covenants to Zomedica that:

(i)As of the Effective Date, it has, or will have during the Term of this Agreement, the full right, power and authority to grant to Zomedica the licenses hereunder granted in this Agreement;

(ii)As of the Effective Date, there is no suit or legal proceeding pending or threatened in writing with respect to the Seraspec Technology and it is has no actual knowledge or notice of any infringement of any third party intellectual property by it that would arise in conducting the activities contemplated by this Agreement;

(iii)To the knowledge of Seraph, all Licensed Patents that have issued are valid and enforceable.

(iv)As of the Effective Date, Seraph has not entered, and during the Term, will not enter, into any written agreement with a third party that conflicts with the rights granted to Zomedica hereunder or Seraph’s ability to fully perform its obligations herein;

(v)Seraph has not entered into any written agreement with a third party to conduct research with respect to the Seraspec Technology in the Zomedica Field of Use, other than Zomedica, and Seraph is not collaborating with any third parties, other than Zomedica, for the development of the Product in the Zomedica Field of Use;

(vi)Exhibit A accurately lists all Licensed Patents as of the Effective Date;

(vii)That other than with respect to an obligation to assign rights to Wayne State University, its representatives contributing and conducting activities under this Agreement on behalf of Seraph, including with respect to the Development Plan, all have assigned and have a duty to assign their rights and contributions with respect to any Intellectual Property developed pursuant to this agreement to Seraph and to no other party;

26

(viii)The WSU Agreement is valid, binding and in full force and effect and is enforceable by Seraph in accordance with its terms. Seraph has performed all material obligations required to be performed by it to date under the WSU Agreement and Seraph has not received any written notice of breach under the WSU Agreement, whether or not cured or disputed, and to Seraph's knowledge, no event has occurred which with the passage of time or giving of notice or both would constitute such a breach or default. There is no existing breach or default by WSU and no event has occurred which with the passage of time or giving notice of or both would constitute such a breach or default by WSU.

(ix)Seraph will throughout the Term comply with the terms and provisions of the WSU Agreement in all material respects, and will not knowingly take any action that it knows or should know, will result in a breach of the WSU Agreement. Seraph will not at any time during the Term terminate the WSU Agreement without the prior written consent of Zomedica. Seraph will not agree to any amendment, waiver of rights, or modification of the WSU Agreement that would reasonably be expected to result in, or would reasonably be expected to have, any other material negative effect or other material adverse impact on (A) any financial or reporting obligation of Zomedica or (B) on the rights granted to Zomedica under this Agreement or the material obligations imposed on Zomedica under this Agreement, without the prior written consent of Zomedica. Seraph shall pay all Sublicense Fees (as defined in the WSU Agreement) when due under the WSU Agreement.

(x)Upon Seraph's receipt of notification from WSU of Seraph's breach of the WSU Agreement, or Seraph's notification to WSU of WSU's breach of the WSU Agreement, and upon expiration or termination of the WSU Agreement, Seraph shall provide notice of such breach, expiration or termination to Zomedica within ten (10) business days in accordance with the notice provisions set forth in this Agreement. Seraph shall further obligate its counsel to likewise provide notice to Zomedica of any such breach, expiration or termination of the WSU Agreement within ten (10) business days in accordance with the notice provision set forth in this Agreement.

10.Injunctive Relief. The Parties acknowledge that the Confidential Information is both highly confidential and proprietary and have been developed by the Parties with substantial effort and at substantial cost, and, therefore, have value to the Parties; and that the breach of any of the provisions of this Agreement may cause the Disclosing Party irreparable injury for which there may be no adequate remedy at law. Accordingly, each Disclosing Party shall have the right, in addition to any other rights it may have, to seek specific performance or other injunctive relief to prevent or restrain the breach of this Agreement by each Receiving Party without the necessity for the securing or posting of any bond in connection with such remedy.

27

11.Term and Termination.

(a)Term. This Agreement shall be effective on the Effective Date and shall extend until the seven (7) year anniversary of the First Commercial Shipment, subject to adjustment pursuant to Sections 6(b) and 6(c) (the "Term"). The Term shall automatically renew for additional one (1) year periods, until (i) either Party delivers written notice of such Party's intent not to renew this Agreement provided no later than ninety (90) days prior to the end of the then-current Term; or (ii) this Agreement is terminated pursuant to this Article 11, whichever occurs first.

(b)Termination by Mutual Agreement. The Parties may terminate this Agreement, in whole or in part, and at such time and with such effect, as may be mutually agreed upon in writing.

(c)Termination for Material Breach. Either Party may terminate this Agreement in its entirety upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within thirty (30) days after receipt of such notice.

(d)Termination by Seraph for Patent Challenge. Seraph may terminate this Agreement in its entirety immediately upon written notice to Zomedica if Zomedica or its Affiliates (directly or indirectly, individually or in association with any other person or entity) challenges the validity, enforceability or scope of any Licensed Patent or trade secret of Seraph anywhere in the world.

(e)Termination for Change of Control. In the event either Party undergoes a Change in Control pursuant to which the resulting entity is a Competitor of the other Party, then such other Party may elect to terminate this Agreement with thirty (30) days’ written notice to the Party undergoing the Change in Control. Each Party will promptly notify the other Party in writing in the event of a Change in Control during the Term or the Post Term Period.

(f)Termination for Bankruptcy. To the extent permitted under applicable law, if at any time during the Term of this Agreement, an Event of Bankruptcy relating to either Party (the "Bankrupt Party") occurs, the other Party (the "Non-Bankrupt Party") shall have, in addition to all other legal and equitable rights and remedies available hereunder, (i) the exclusive option, exercisable on written notice to the Bankrupt Party, to negotiate a fully paid-up license to any intellectual property owned by the Bankrupt Party and necessary to independently continue commercialization of the Seraspec Technology in the Zomedica Field of Use; or (ii) the option to terminate this Agreement upon sixty (60) days written notice to the Bankrupt Party.

28

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

(g)Non-Exclusive Distribution Rights for the Post-Term Period. Notwithstanding anything to the contrary, in the event of any expiration or termination of this Agreement, Zomedica may continue to distribute, market and promote sales of the Seraspec Consumables for use in the Zomedica Field of Use in the Territory on a non-exclusive basis for a period of [*] from the effective date of such expiration or termination (the "Post Term Period”). Seraph will continue to supply the Seraspec Consumables to Zomedica during the Post Term Period at the pricing set forth in this Agreement; in each case, subject to the terms and conditions of this Section 11(g). All provisions of this Agreement will continue to apply during the Post Term Period, including without limitation the applicable License Fees set forth in Section 5(e), with the following exceptions:

(i)the license granted to Zomedica pursuant to Section 2(a) shall automatically convert to non-exclusive during the Post Term Period;

(ii)Section 2(e) ("Exclusivity") shall not apply during the Post Term Period;

(iii)Section 2(f) ("Right of First Offer") shall not apply during the Post Term Period;

(iv)the rights granted to Zomedica pursuant to Section 4(a) ("Distribution Rights") shall automatically convert to non-exclusive during the Post Term Period, and such non-exclusive rights shall no longer be subject to minimum performance objectives set forth in Section 6;

(v)Section 6 ("Performance Metrics; Competitors, Claw-Back of Rights") shall not apply during the Post Term Period;

(vi)Section 7(d)(ii) ("Enforcement by Zomedica") shall not apply during the Post Term Period; and

(vii)Section 11(d)(ii) shall not apply during the Post Term Period.

(h)Survival. Notwithstanding the foregoing, Sections 1, 3(d)(ii), 3(d)(iii), 4(e)(ii), 4(f), 4(h)(but only with respect to the obligation to provide First Tier Customer Support and Second Tier Customer Support), 5(i), 5(j), 7, 8, 10, 11, 12, and 14-19 shall survive expiration or termination of this Agreement. In addition, except as provided in Section 11(g), all provisions of this Agreement shall survive the expiration or termination of this Agreement until the end of the Post Term Period.

29

12.Indemnification.

(a)Each Party agrees to defend, indemnify and hold harmless the other Party, their directors, officers, employees and agents from any loss, claim, damage or liability of any kind whatsoever arising from a third party claim, demand or cause of action against such Party seeking indemnification, which may arise from the indemnifying Party’s breach of this Agreement or gross negligence or willful misconduct in its performance hereunder, except to the extent such loss, claim, damage or liability arises due to the gross negligence, willful misconduct, or breach of this Agreement by the indemnified Party; provided, in each case, that (i) the indemnifying Party receives prompt notice of any such claim, demand or cause of action, (ii) the indemnifying Party shall not be obligated to indemnify the other Party for any claim, demand or cause of action in connection with any settlement made by the indemnified Party unless the indemnifying Party consents in writing to such settlement, such consent not to be unreasonably withheld, and (iii) the indemnifying Party shall have the exclusive right to control the defense and settlement any such claim, demand or cause of action, except that the indemnifying Party shall not settle or consent to an adverse judgment for such claim, demand or cause of action without the express written consent of the indemnified Party, such consent not to be unreasonably withheld. The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party.

(b)Except with respect to the willful misconduct OR GROSS NEGLIGENCE by a Party, BREACH OF A PARTY’S OBLIGATIONS OF CONFIDENTIALITY HEREUNDER, or FOR AMOUNTS SOUGHT BY THIRD PARTIES IN CLAIMS THAT ARE SUBJECT TO THE PARTIES’ RESPECTIVE INDEMNITY OBLIGATIONS UNDER THIS SECTION 12, neither Party will be liable with respect to any matter arising under this Agreement under any contract, negligence, strict liability or other legal or equitable theory for any punitive, exEmplAry, incidental, indirect or consequential damages, including but not limited to, loss of business or good will, loss of revenue or lost profits.

13.Scope of Agreement. This Agreement does not constitute or create a joint venture, partnership or agency or other cooperative relationship between the Parties, but merely defines the rights, duties and obligations of the Parties with respect to the activities contemplated hereby, as independent contractors.

14.Severability. If any term or provision of this Agreement, or the application thereof to any circumstances shall, to any extent and for any reason, be held to be invalid or unenforceable, the remainder of this Agreement, or the application of such term or provision to circumstance other than those to which it is held invalid or unenforceable, shall not be affected thereby and shall be construed as if such invalid or unenforceable term or provision had never been contained herein, and each term and provision shall be valid and enforceable to the fullest extent permitted by law.

15.Notices. Any notice required or permitted hereunder shall be given in writing and delivered (a) personally, (b) by express courier, or (c) by telex, facsimile or electronic mail, followed by registered or certified mail, return receipt requested, postage prepaid, to the Party entitled thereto at the address for such Party shown in the introductory paragraph of this Agreement. Either Party may change such address by giving notice to the other of such change in the manner contemplated by this Section. The return receipt, the delivery receipt, electronic confirmation of receipt, or the affidavit of messenger will be deemed conclusive but not exclusive evidence of delivery; delivery will also be presumed at such time as delivery is refused by the addressee upon presentation.

30

16.Binding Effect. This Agreement shall inure to the benefit of and be binding on the Parties hereto and their respective legal representatives, successors and permitted assignees.

17.Modification. This Agreement may not be modified by any Party except by a writing executed by both Parties.

18.Governing Law. This Agreement shall be governed and construed in accordance with the laws of the State of Michigan, without giving effect to its conflict of laws principles or rules.

19.Assignment. Neither Party may assign this Agreement or its rights and/or obligations hereunder to another party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however that either Party may, without the prior written consent of the other Party, assign this Agreement and its rights and/or obligations hereunder to an Affiliate or to any successors to substantially all of its business to which this Agreement pertains or in the event of a merger or consolidation with another company provided that such successor is not a Competitor of the other Party.

20.Entire Agreement. This Agreement represents the entire agreement between the Parties with respect to the subject matter hereof and incorporates all previous agreements between the Parties, whether written or oral, with respect to such subject matter.

21.Counterparts. This Agreement may be executed in two or more counterparts, each of which counterpart shall be deemed an original, but all of which counterparts taken together shall be one and the same document.

22.Facsimile Signatures. Facsimile or electronic copies of signatures to this Agreement shall be considered originals hereof, with any Party executing this Agreement by facsimile or pdf signature agreeing to provide promptly to the other Party an original signature evidencing the same.

Signatures on the Following Page

31

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed on the day and year first above written.

Seraph Biosciences, Inc.	Zomedica Pharmaceuticals Corp.
By:	By:
Name:	Name:
Title:	Title:

Signature Page to Commercialization and Exclusive Distribution Agreement

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

EXHIBIT A

LICENSED PATENTS

The Licensed Patents under this Agreement shall include at least the following patent assets. The Parties understand and acknowledge that additional patents may be added to this Exhibit from time to time.

[*]

Exhibit A - 1

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

EXHIBIT B

STATEMENT OF WORK: VERIFICATION AND VALIDATION WORK FOR FECAL AND URINE MATRICES ONLY

[*]

Exhibit B -1

EXHIBIT C

[Intentionally omitted]

Exhibit C -1

EXHIBIT D

PRIVATE PLACEMENT AND REGISTRATION RIGHTS RIDER

(a)In connection with the issuance of Zomedica shares to Seraph, Seraph makes the following representations and warranties to Zomedica set forth in subsection (b) below, and Zomedica makes the following covenants to Seraph, set forth in subsections (c) – (t) below.

(b)Seraph hereby represents and warrants to Zomedica as follows:

(i)On the date hereof and on each date on which it receives Zomedica common shares hereunder (collectively, the “Securities”), Seraph is and will be an “accredited investor” as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”). Seraph maintains its principal executive office at the location specified in the introductory paragraph of this Agreement.

(ii)The Securities to be received by Seraph hereunder will be acquired for Seraph’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and Seraph has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to Seraph’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by Seraph to hold the Securities for any period of time. Seraph is not a broker-dealer registered with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or an entity engaged in a business that would require it to be so registered.

(iii)Seraph acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.

(iv)Seraph has had an opportunity to receive all information related to Zomedica requested by it and to ask questions of and receive answers from Zomedica regarding Zomedica, its business and the terms and conditions of the Securities. Seraph acknowledges that it has had access to Zomedica’s filings with the Commission as well as filings made by Zomedica with applicable Canadian securities regulators.

(v)Seraph understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from Zomedica in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances.

Exhibit D -1

(vi)Seraph did not learn of the investment in the Securities as a result of any general solicitation or general advertising.

(vii)Seraph acknowledges and understands that because Zomedica was previously a “shell company” as defined in Rule 405 under the Securities Act, the provisions of Rule 144(i) under the Securities Act will apply with respect to any resale of the Securities pursuant to such Rule 144.

(viii)Seraph acknowledges and understands that certificates evidencing the Securities will bear the following or any similar legend:

“The securities represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities are sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended.”

(c)Following the issuance of any Securities to Seraph under the Agreement, Zomedica shall use its commercially reasonable efforts to register such Securities for resale or other disposition by Seraph within 90 days of the date of such receipt. Zomedica shall notify Seraph promptly upon effecting such registration. Subject to any permitted “Black-Out Periods” (as described below), Zomedica shall use its commercially reasonable efforts to maintain the effectiveness of any such registration until the earlier of (i) the date on which all of the Securities so registered have been sold by Seraph or its transferees or (ii) the date on which such Securities may be sold under Rule 144 (the period of such registration being referred to herein as the “Registration Period”). Subject to any comments from the staff of the Commission, such Registration Statement shall include the plan of distribution attached hereto as Exhibit A;

Exhibit D -2

(d)Zomedica shall have the right to suspend its obligation to register the Securities as provided in clause (c) above or to maintain the registration of such Securities during the Registration Period and the use of any prospectus during the Registration Period as follows: (i) (A) if the registration statement registering the Securities is on Form S-1, for a period commencing on the earlier of (I) the public announcement by Zomedica of its financial results for any fiscal year or (II) the filing by Zomedica of its Annual Report on Form 10-K for such fiscal year, until in either case a post-effective amendment to such registration statement containing audited financial statements for such fiscal year is declared effective by the Commission, or (B) if the registration statement registering the Securities is on Form S-3, for a period, if any, commencing on the public announcement by Zomedica of its financial results for any fiscal year until the filing by Zomedica of its Annual Report on Form 10-K for such fiscal year, (ii) for such period of time as determined by Zomedica in the good faith exercise of its business judgment if Zomedica furnishes to Seraph a certificate signed by Zomedica’s chief executive officer or chief financial officer stating that in his or her good faith judgment it would be materially detrimental to Zomedica and its shareholders for such registration statement to either become effective or remain effective because such action would (A) materially delay, hinder or otherwise interfere with a material acquisition, corporate reorganization, collaboration, joint venture or other similar transaction involving Zomedica; (B) require the disclosure of material non-public information that Zomedica has a bona fide business purpose for preserving as confidential; (C) render Zomedica unable to comply with requirements under the Securities Act or Exchange Act, then Zomedica shall have the right to defer taking action with respect to such filing; or (D) interfere in any material respect with a proposed capital raise by Zomedica; or (iii) for such period of time as determined by Zomedica to amend or supplement the registration statement or prospectus covering such Securities so that registration statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading. Each of such periods is referred to herein as a “Black-Out Period.” Except for any Black-Out Period arising pursuant to clause (i) above, no Black-Out Period shall continue for more than 60 days and the total Black-Out Periods in any 12-month period shall not exceed a total of 120 days. During any Black-Out Period (other than a Black-Out Period covered by clause (ii)(D) above), Zomedica shall not effect the registration of securities for its own account or the account of another selling shareholder. Zomedica shall promptly (i) notify Seraph in writing of the commencement of a Black-Out Period, but shall not (without the prior written consent of Seraph) disclose to Seraph any material non-public information giving rise to a Black-Out Period, (ii) advise Seraph in writing to cease all sales of the Securities under the related registration statement and prospectus until the end of the Black-Out Period and (iii) use its commercially reasonable efforts to terminate a Black-Out Period as promptly as practicable.

(e)Except during a Black-Out Period, Zomedica shall promptly notify Seraph, at any time prior to the end of the Registration Period, upon discovery that, or upon the happening of any event as a result of which, the registration statement or prospectus covering the Securities includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading, and promptly (but in any event within thirty (30) days) prepare, file with the Commission and furnish to Seraph (including delivery pursuant to Rule 172 under the Securities Act) a supplement to or an amendment of such registration statement or prospectus as may be necessary to correct such misstatement or omission.

(f)Seraph shall furnish in writing to Zomedica the information set forth in the selling shareholder’s questionnaire attached hereto as Exhibit B to effect the registration of such Securities and shall execute such documents in connection with such registration as Zomedica may reasonably request. Seraph shall provide such information to Zomedica at least two (2) business days prior to the first anticipated filing date of the related registration statement. In the event that Seraph fails to provide a completed questionnaire on a timely basis and such failure continues for a period of seven (7) business days after Zomedica provides Seraph with written notice of such failure, Zomedica’s obligation to register such Securities shall terminate with respect to such Securities; provided, however that such failure shall not affect Zomedica’s registration obligations with respect to any other Securities issued to Seraph.

Exhibit D -3

(g)Seraph agrees to cooperate with Zomedica as reasonably requested by Zomedica in connection with the preparation and filing of a registration statement hereunder, unless Seraph has notified Zomedica in writing of its election to exclude its Securities from such registration statement

(h)Seraph agrees that, upon receipt of any notice from Zomedica (i) during any permitted Black-Out Period or (ii) the happening of an event pursuant to clause (e) above, Seraph will immediately discontinue disposition of Securities pursuant to the registration statement covering such Securities, until such permitted Black-Out Period has ended or Seraph is advised by Zomedica that such dispositions may again be made.

(i)If at any time following the date of this Agreement that any Securities are not eligible for sale under Rule 144 (i) there is not one or more effective registration statements covering the Securities and (ii) Zomedica proposes for any reason to register any Common Shares under the Securities Act (other than pursuant to a registration statement on Form S-4 or Form S-8 (or a similar or successor form)) with respect to an offering of Common Shares by Zomedica for its own account or for the account of any of its shareholders, it shall at each such time promptly give written notice to Seraph of its intention to do so (but in no event less than twenty (20) days before the anticipated filing date) and, to the extent permitted under the provisions of Rule 415 under the Securities Act (if the registration is a shelf registration) and pari passu with the terms of any registration rights granted to other shareholders, include in such registration all Securities with respect to which Seraph requests in writing be included therein within ten (10) days after receipt of Zomedica’s notice. Such notice shall offer Seraph the opportunity to register such number of Securities as Seraph may request and shall indicate the intended method of distribution of securities covered by such registration statement.

(j)Notwithstanding the foregoing, (i) if Seraph has exercised its option to include some or all of its Securities in an offering under (i) above, and such registration involves an underwritten public offering, (A) Seraph must sell its Securities to, if applicable, the underwriter(s) at the same price and subject to the same underwriting discounts and commissions that apply to the other securities sold in such offering and subject to Seraph entering into customary underwriting documentation for selling shareholders in an underwritten public offering, and (B) Seraph’s right to include Securities in such registration shall be subject to cut-back (pro rata with any other selling shareholders seeking to include their securities in such registration) in the event that the managing underwriter of such offering determines that the inclusion of all or some of such Securities would be impracticable or inadvisable, and (ii) if, at any time after giving written notice of its intention to register any Securities pursuant to clause (i) above and prior to the effective date of the registration statement filed in connection with such registration, Zomedica shall determine for any reason not to cause such registration statement to become effective under the Securities Act, Zomedica shall deliver written notice to Seraph and, thereupon, shall be relieved of its obligation to register any Securities in connection with such registration.

Exhibit D -4

(k)In connection with the registration of Securities hereunder, Zomedica shall:

(i)Except during any Black-Out Period, prepare and file with the Commission such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

(ii)make available to Seraph an electronic copy of the preliminary and final prospectus in accordance with Rule 173, or in the alternative, furnish such numbers of hard copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as Seraph may reasonably request in order to facilitate their disposition of their Securities;

(iii)promptly notify Seraph of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;

(iv)use its commercially reasonable efforts to cause all such Securities covered by such registration statement to be listed on each securities exchange and trading system (if any) on which similar securities issued by Zomedica are then listed;

(v)provide a transfer agent and registrar for all Securities registered pursuant to this Agreement and provide a CUSIP number for all such Securities, in each case not later than the effective date of such registration;

(vi)notify Seraph promptly after Zomedica receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed;

(vii)after such registration statement becomes effective, notify Seraph of any request by the Commission that Zomedica amend or supplement such registration statement or prospectus; and,

(viii)in connection with any sale or other disposition of Securities pursuant to Rule 144, cooperate with Seraph to effect the removal of any restrictive legend in connection with such sale or other disposition and, in connection therewith, cause its counsel to provide to the transfer agent for the Securities a customary opinion of counsel that such legend may be removed in connection with such sale or other disposition provided Seraph has provided to Zomedica such documentation, including a customary broker’s letter, as Zomedica’s counsel may reasonably request in connection with such opinion.

Exhibit D -5

(l)Zomedica will pay all of its expenses associated with effecting the registration of the Securities or removal of any Rule 144 legend, including filing and printing fees, Zomedica’s counsel and accounting fees and expenses, costs associated with clearing the Securities for sale under applicable state securities laws and listing and transfer agent fees. Seraph shall be responsible for its own fees and expenses in connection with any such registration, including its counsel and accounting fees, discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Securities being sold.

(m)To the extent permitted by law, Zomedica will indemnify and hold harmless Seraph and its officers and directors and each person, if any, who controls Seraph within the meaning of the Securities Act (collectively, “Seraph Indemnified Parties”), against any Damages (defined below), and Zomedica will promptly reimburse such Seraph Indemnified Parties for all reasonable out-of-pocket costs and expenses (including the reasonable fees and disbursements of counsel) in connection with investigating or defending any claim or proceeding for Damages as such costs and expenses are incurred; provided, however, that the indemnity agreement contained in this subsection (m) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of Zomedica, which consent shall not be unreasonably withheld, nor shall Zomedica be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of Seraph expressly for use in connection with such registration.

(n)To the extent permitted by law, Seraph will indemnify and hold harmless Zomedica, and each of its directors, each of its officers who has signed the registration statement and each person, if any, who controls Zomedica within the meaning of the Securities Act (collectively, “Zomedica Indemnified Party”) against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of Seraph expressly for use in connection with such registration; and Seraph will promptly reimburse such Zomedica Indemnified Parties for all reasonable out-of-pocket costs and expenses (including the reasonable fees and disbursements of counsel) in connection with investigating or defending any claim or proceeding for Damages as such costs and expenses are incurred; provided, however, that the indemnity agreement contained in this subsection (n) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of Seraph, which consent shall not be unreasonably withheld; and provided, further, that in no event shall the aggregate amounts payable by Seraph by way of indemnity or contribution under this subsection (m) exceed the gross proceeds received by Seraph from the sale of Securities pursuant to such registration.

(o)As used herein, the term “Damages” shall mean any loss, damage, or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement, prospectus, “blue sky” application or other document or amendment or supplement thereto; or (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein, in the case of a registration statement, not misleading, and, in any other case, in light of the circumstances under which they were made, not misleading.

Exhibit D -6

(p)Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its outside counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person but shall have the right to participate therein at its sole expense with counsel of its choice); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.

(q)To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Agreement but it is judicially determined that such indemnification may not be enforced in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Agreement, then, and in each such case, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall Seraph’s liability pursuant to this section (q), when combined with the amounts paid or payable by Seraph pursuant to section (n), exceed the gross proceeds received by Seraph from the sale of Securities pursuant to such registration.

(r)Seraph’s registration rights as contained herein are personal to Seraph and may not be assigned or otherwise transferred by Seraph, whether in connection with the sale or other disposition of Securities or otherwise. Any purported assignment or other transfer shall be null and void ab initio.

Exhibit D -7

(s)Zomedica shall, at all times while Zomedica is subject to Sections 13(a) or 15(d) under the Exchange Act, use commercially reasonable efforts to (i) make and keep public information available, as those terms are understood and defined in Rule 144; and (ii) file with the Commission in a timely manner all reports and other documents required of Zomedica under the Securities Act and the Exchange Act.

(t)To the extent applicable, Zomedica shall use commercially reasonable efforts to register or qualify Securities under U.S. state securities or “blue sky” laws as Seraph may reasonably request; provided, however, that Zomedica shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction, (ii) subject itself to general taxation, or (iii) file a general consent to service of process in any such jurisdiction.

Exhibit D -8

Exhibit A

Plan of Distribution

The selling shareholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling common shares or interests in common shares received after the date of this prospectus from a selling shareholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their common shares or interests in common shares on any stock exchange, market or trading facility on which the common shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

The selling shareholders may use any one or more of the following methods when disposing of common shares or interests therein:

·ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

·block trades in which the broker-dealer will attempt to sell the common shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

·purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

·an exchange distribution in accordance with the rules of the applicable exchange;

·privately negotiated transactions;

·short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

·through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

·broker-dealers may agree with the selling shareholders to sell a specified number of common shares at a stipulated price per share;

·a combination of any such methods of sale; and

·any other method permitted by applicable law.

The selling shareholders may, from time to time, pledge or grant a security interest in some or all of the common shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the common shares, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may transfer the common shares in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

Exhibit D -9

In connection with the sale of our common shares or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common shares in the course of hedging the positions they assume. The selling shareholders may also sell common shares short and deliver these common shares to close out their short positions, or loan or pledge the common shares to broker-dealers that in turn may sell these common shares. The selling shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of common shares offered by this prospectus, which common shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The aggregate proceeds to the selling shareholders from the sale of the common shares offered by them will be the purchase price of the common shares less discounts or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common shares to be made directly or through agents. We will not receive any of the proceeds from this offering.

The selling shareholders also may resell all or a portion of the common shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule.

The selling shareholders and any underwriters, broker-dealers or agents that participate in the sale of the common shares or interests therein may be "underwriters" within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the common shares may be underwriting discounts and commissions under the Securities Act. Selling shareholders who are "underwriters" within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.

To the extent required, the common shares to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

In order to comply with the securities laws of some states, if applicable, the common shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common shares may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

Exhibit D -10

We have advised the selling shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of common shares in the market and to the activities of the selling shareholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify any broker-dealer that participates in transactions involving the sale of the common shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to indemnify the selling shareholders against liabilities under the Securities Act relating to the registration of the common shares offered by this prospectus.

We have agreed with the selling shareholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (i) the date on which all of the common shares have been sold by the selling shareholders or (ii) the date on which the common shares may be sold under Rule 144.

Exhibit D -11

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

EXHIBIT E

CUSTOMER SERVICE REQUIREMENTS AND WARRANTY GUIDELINES

[*]

Exhibit E - 1

[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

EXHIBIT F

MANUFACTURING DOCUMENTATION AND RECORDKEEPING REQUIREMENTS

[*]

Exhibit F - 1

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Gerald Solensky, Jr., certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2018 of Zomedica Pharmaceuticals Corp.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
		c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
		d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting

Date: August 9, 2018

/s/ Gerald Solensky, Jr.

Gerald Solensky Jr.

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Shameze Rampertab, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2018 of Zomedica Pharmaceuticals Corp.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
		a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
		b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
		c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
		d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
		a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
		b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2018

/s/ Shameze Rampertab

Shameze Rampertab

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

In connection with the Quarterly Report on Form 10-Q of Zomedica Pharmaceuticals Corp. (the “Company”) for the three month period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Gerald Solensky Jr., President and Chief Executive Officer of the Company, and Shameze Rampertab, Chief Financial Officer for the Company, hereby certify, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2018	By:	/s/ Gerald Solensky Jr.
		Gerald Solensky Jr.
		Chief Executive Officer
		(Principal Executive Officer)

Date: August 9, 2018	By:	/s/ Shameze Rampertab
		Shameze Rampertab.
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

This Certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document And Entity Information	6 Months Ended
	Jun. 30, 2018 shares
Document Information [Line Items]
Entity Registrant Name	Zomedica Pharmaceuticals Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)	94,511,209
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML

Condensed Unaudited Interim Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 4,279,163	$ 3,448,147
Prepaid expenses and deposits	1,135,234	786,273
Trade and other receivable	49,627	28,272
	5,464,024	4,262,692
Prepaid expenses and deposits	495,481	566,832
Property and equipment	444,692	371,157
Intangible assets	13,762	15,141
	6,417,959	5,215,822
Current liabilities:
Accounts payable and accrued liabilities	1,683,802	828,737
	1,683,802	828,737
Shareholders' equity:
Capital stock, authorized unlimited common shares without par value, issued and outstanding 94,511,209 common shares (2017 - 90,225,869)	25,258,124	18,244,659
Additional paid-in capital	1,417,860	1,768,526
Accumulated deficit	(21,941,827)	(15,626,100)
	4,734,157	4,387,085
	$ 6,417,959	$ 5,215,822

XML

Condensed Unaudited Interim Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Capital stock, unlimited common shares authorized	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, shares issued (in shares)	94,511,209	90,225,869
Capital stock, shares outstanding (in shares)	94,511,209	90,225,869

XML

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Expenses:
Research and development	$ 2,534,620	$ 504,235	$ 3,134,961	$ 1,120,684
General and administrative	1,248,490	748,610	2,408,662	1,575,635
Professional fees	336,455	314,658	708,402	696,194
Amortization	693	700	1,379	1,399
Depreciation	27,459	22,782	64,158	43,090
Loss from operations	4,147,717	1,590,985	6,317,562	3,437,002
Gain on settlement of liabilities				(5,000)
Foreign exchange gain	(3,319)	(2,615)	(1,835)	(10,896)
Loss before income taxes	4,144,398	1,588,370	6,315,727	3,421,106
Income tax expense
Net loss and comprehensive loss	$ 4,144,398	$ 1,588,370	$ 6,315,727	$ 3,421,106
Weighted average number of common shares - basic and diluted (in shares)	92,527,470	87,077,768	91,527,862	85,622,780
Loss per share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.02)	$ (0.07)	$ (0.04)

XML

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)		Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		83,964,569
Balance at Dec. 31, 2016		$ 10,189,973		$ 1,205,456	$ (7,561,028)	$ 3,834,401
Stock issuance for services (in shares)		43,613
Stock issuance for services		$ 45,000				45,000
Stock issuance for financing, net of costs (in shares)		2,902,682
Stock issuance for financing, net of costs		$ 3,215,876				3,215,876
Stock-based compensation				161,590		$ 161,590
Stock issued due to exercise of options (in shares)		497,060				497,060
Stock issued due to exercise of options		$ 53,707		(14,163)		$ 39,544
Net loss for the period					(3,421,106)	(3,421,106)
Balance (in shares) at Jun. 30, 2017		87,407,924
Balance at Jun. 30, 2017		$ 13,504,556		1,352,883	(10,982,134)	3,875,305
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659		1,768,526	(15,626,100)	4,387,085
Stock issuance for services (in shares)	[1]	641,717
Stock issuance for services		$ 1,238,513	[1]			1,238,513
Stock issuance for financing, net of costs (in shares)	[2]	1,861,627
Stock issuance for financing, net of costs		$ 3,978,690	[2]			3,978,690
Stock-based compensation				7,288		$ 7,288
Stock issued due to exercise of options (in shares)		1,781,996				1,781,996
Stock issued due to exercise of options		$ 1,796,262		(357,954)		$ 1,438,308
Net loss for the period					(6,315,727)	(6,315,727)
Balance (in shares) at Jun. 30, 2018		94,511,209
Balance at Jun. 30, 2018		$ 25,258,124		$ 1,417,860	$ (21,941,827)	$ 4,734,157

[1] On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

[2] On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

XML

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Cash flows used in operating activities:
Net loss for the period	$ (4,144,398)	$ (1,588,370)	$ (6,315,727)	$ (3,421,106)
Adjustments for
Depreciation	27,459	22,782	64,158	43,090
Amortization	693	700	1,379	1,399
Stock issued for services	1,238,513		1,238,513	45,000
Stock-based compensation	1,597		7,288	161,590
Change in non-cash operating working capital
Trade and other receivable	19,754	7,288	(21,355)	3,109
Prepaid expenses	(241,270)	(22,434)	(247,764)	(60,399)
Deposits	(60,320)	1,391	(29,846)	(215,421)
Accounts payable and accrued liabilities	417,477	(533,321)	855,065	(223,028)
	(2,740,495)	(2,111,964)	(4,448,289)	(3,665,766)
Cash flows from financing activities:
Cash proceeds from financing	4,002,496	3,000,000	4,002,496	3,250,000
Cash received from stock option exercises	30,522	22,395	1,438,308	39,544
Cash paid on stock issuance costs	(23,806)	(25,260)	(23,806)	(34,124)
Repayments of shareholder loan				(6,726)
	4,009,212	2,997,135	5,416,998	3,248,694
Cash flows used in investing activities:
Investment in property and equipment	(124,474)	(2,398)	(137,693)	(159,800)
	(124,474)	(2,398)	(137,693)	(159,800)
Increase (decrease) in cash and cash equivalents	1,144,243	882,773	831,016	(576,872)
Cash and cash equivalents, beginning of period	3,134,920	1,767,035	3,448,147	3,226,680
Cash and cash equivalents, end of period	$ 4,279,163	$ 2,649,808	$ 4,279,163	$ 2,649,808

XML

Note 1 - Nature of Operations and Going Concern

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

1. Nature of operations and going concern

Zomedica Pharmaceuticals Corp. (the “Company”) was incorporated on

January 7, 2013

under the Alberta Business Corporations Act as Wise Oakwood Ventures Inc. (“WOW”) and was classified as a capital pool company, as defined in Policy

2.4

of the TSX Venture Exchange.

On

April 21, 2016,

the Company closed its qualifying transaction (“Transaction”) with ZoMedica Pharmaceuticals Inc. (“ZoMedica”), and filed Articles of Amalgamation and amalgamated with

9674128

Canada Inc. which was wholly-owned by WOW. The amalgamated company changed its name to Zomedica Pharmaceuticals Ltd. and WOW subsequently changed its name to Zomedica Pharmaceuticals Corp. The shares of Zomedica Pharmaceuticals Corp. began trading under the new symbol “ZOM” on Monday

May 2, 2016

on the TSX Venture Exchange. On

June 21, 2016,

the Company filed Articles of Amalgamation and vertically amalgamated with its wholly-owned subsidiary, Zomedica Pharmaceuticals Ltd.

Zomedica has

one

corporate subsidiary, Zomedica Pharmaceuticals, Inc., a Delaware company whose results and operations are included in these condensed unaudited interim consolidated financial statements. The Company is a biopharmaceutical company targeting health and wellness solutions for the companion pet through a ground-breaking approach that focuses on the needs of the veterinarians themselves. Zomedica's head office is located at

100

Phoenix Drive, Suite

190,

Ann Arbor, MI

48108

and its registered office is located at Suite

1250,

639

–

5th

Avenue S.W., Calgary, Alberta

T2P

0M9.

Going concern

These condensed unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Accordingly, they do

not

give effect to adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business and at amounts different from those in the accompanying condensed consolidated financial statements. Such adjustments could be material.

XML

Note 2 - Basis of Preparation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Basis of Accounting [Text Block]

2. Basis of preparation

The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements.

Basis of consolidation

These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc.

All inter-company accounts and transactions have been eliminated on consolidation.

XML

Note 3 - Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

3. Significant accounting policies

Use of estimates

The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.

Basis of measurement

The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.

Functional and reporting currencies

The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency.

The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.

Research and development

Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic

730.

Translation of foreign currencies

In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.

Stock-based compensation

The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated.

The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do

not

require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest.

The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Loss per share

Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were

not

included in the computation of diluted EPS because the Company has incurred a loss for the

six

months ended

June 30, 2018

as the effect would be anti-dilutive.

Comprehensive loss

The Company follows ASC topic

220.

This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. The Company has

no

other comprehensive loss items.

Future accounting pronouncements

In

February 2016,

the FASB issued new guidance, ASU

No.

2016

-

02,

Leases (Topic

842

). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic

842

is effective for annual reporting periods (including interim reporting periods) beginning after

December 15, 2018.

Early adoption is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.

XML

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]

4. Critical accounting judgments and key sources of estimation uncertainty

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are

not

readily apparent from other sources. Actual results

may

differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Critical areas of estimation and judgements in applying accounting policies include the following:

Going concern

These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due.

Useful lives of property and equipment

As described in Note

3

above, the Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and revised service offerings. During the

six

month period ended

June 30, 2018

and

June 30, 2017,

the Company was

not

required to adjust the useful lives of any assets based on the factors described above.

Deferred income taxes

The calculation of deferred income taxes is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets are reviewed at each balance sheet date and adjusted to the extent that it is

no

longer probable that the related tax benefit will be realized.

Stock-based payments

The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends.

XML

Note 5 - Prepaid Expenses and Deposits

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Prepaid Rent [Text Block]

5. Prepaid expenses and deposits

The Company entered into a lease agreement with Wickfield Phoenix LLC effective on

August 23, 2016.

The Company prepaid the full outstanding balance of

$801,973

on

August 26, 2016

and recorded the prepaid rent due within a year as current. As at

June 30, 2018,

the Company has classified

$155,220

as a current asset in the condensed unaudited interim consolidated balance sheet (

December 31, 2017 -

$155,220

).

XML

Note 6 - Property and Equipment

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

6. Property and equipment

	Computer equipment		Furniture and equipment		Laboratory equipment		Leasehold improvements		Total
Cost
Balance at December 31, 2016	$	61,598	$	7,364	$	243,529	$	25,672	$	338,163
Additions		89,557		68,694		2,200		11,285		171,736
Balance at December 31, 2017		151,155		76,058		245,729		36,957		509,899
Additions		22,763		4,172		110,758		-		137,693
Balance at June 30, 2018		173,918		80,230		356,487		36,957		647,592
Accumulated depreciation
Balance at December 31, 2016		13,858		1,490		29,783		3,998		49,129
Depreciation		28,944		10,355		45,092		5,222		89,613
Balance at December 31, 2017		42,802		11,845		74,875		9,220		138,742
Depreciation		20,284		5,754		20,558		17,562		64,158
Balance at June 30, 2018		63,086		17,599		95,433		26,782		202,900
Net book value as at:
December 31, 2017	$	108,353	$	64,213	$	170,854	$	27,737	$	371,157
June 30, 2018	$	110,832	$	62,631	$	261,054	$	10,175	$	444,692

XML

Note 7 - Intangible Assets

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

7. Intangible assets

	Computer software		Trademarks		Total
Cost
Balance at December 31, 2016	$	5,143	$	16,236	$	21,379
Additions		-		-		-
Balance at December 31, 2017		5,143		16,236		21,379
Additions		-		-		-
Balance at June 30, 2018		5,143		16,236		21,379
Accumulated amortization
Balance at December 31, 2016		2,428		1,013		3,441
Amortization		1,715		1,082		2,797
Balance at December 31, 2017		4,143		2,095		6,238
Amortization		842		537		1,379
Balance at June 30, 2018		4,985		2,632		7,617
Net book value as at:
December 31, 2017	$	1,000	$	14,141	$	15,141
June 30, 2018	$	158	$	13,604	$	13,762

XML

Note 8 - Loan Arrangements

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Debt Disclosure [Text Block]

8. Loan arrangements

On

October 17, 2017,

the Company entered into a loan arrangement with a shareholder of the Company, pursuant to which such shareholder has agreed to provide a loan facility to the Company, whereby the Company

may

borrow up to

$5,000,000,

with the proceeds to be used for working capital and general corporate purposes. The term of the loan facility is

five

(

5

) years, with principal and interest payments being due only at the time of maturity. Under the loan agreement, the Company

may

borrow in

one

or more advances, provided however that a minimum amount of

$250,000

must be borrowed at any

one

time and

not

more than

two

advances

may

occur per month. Interest shall accrue at a rate of

fourteen

percent (

14%

) per annum, payable upon maturity. As of

June 30, 2018,

no

amounts have been borrowed.

XML

Note 9 - Capital Stock

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

9. Capital stock

The Company is authorized to issue an unlimited number of common stock, all without par value.

Issued and outstanding common stock:

	Number of common stock		Capital stock
Balance at December 31, 2016		83,964,569	$	10,189,973
Stock issuance for services		43,613		45,000
Stock issued due to exercise of options		497,060		53,707
Stock issuance for financing, net of costs		2,902,682		3,215,876
Balance at June 30, 2017		87,407,924	$	13,504,556
Balance at December 31, 2017		90,225,869	$	18,244,659
Stock issuance for services (i)		641,717		1,238,513
Stock issued due to exercise of options (Note 10)		1,781,996		1,796,262
Stock issuance for financing, net of costs (ii)		1,861,627		3,978,690
Balance at June 30, 2018		94,511,209	$	25,258,124

i. On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

ii. On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

XML

Note 10 - Stock-based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10. Stock-based compensation

During the

three

months ended

June 30, 2018,

154,000

options were exercised. During the

three

months ended

June 30, 2017,

87,060

options were exercised. During the

six

months ended

June 30, 2018,

1,781,996

options were exercised. During the

six

months ended

June 30, 2017,

497,060

options were exercised and the Company issued

535,000

stock options, each option entitling the holder to purchase

one

common share of the Company.

The continuity of stock options are as follows:

	Number of Options			Weighted Avg Exercise Price (CDN$)
Balance at December 31, 2016		7,975,000			0.84
Stock options exercised on February 21, 2017		(10,000	)		0.25
Stock options exercised on February 21, 2017		(400,000	)		0.05
Options issued on February 24, 2017		535,000			1.50
Stock options exercised on May 8, 2017		(7,060	)		1.50
Stock options cancelled on May 17, 2017		(10,000	)		1.50
Stock options exercised on May 23, 2017		(80,000	)		0.25
Stock options exercised on July 6, 2017		(200,000	)		0.05
Stock options exercised on July 17, 2017		(220,000	)		0.25
Options issued on August 14, 2017		1,280,000			2.75
Stock options exercised on August 29, 2017		(7,940	)		1.50
Stock options exercised on December 19, 2017		(25,000	)		0.25
Stock options exercised on December 19, 2017		(750,000	)		1.50
Balance at December 31, 2017		8,080,000			1.21
Stock options exercised on January 8, 2018		(124,000	)		0.25
Stock options exercised on January 26, 2018		(100,000	)		0.25
Stock options exercised on March 8, 2018		(50,000	)		0.25
Stock options exercised on March 13, 2018		(176,000	)		0.25
Stock options exercised on March 22, 2018		(50,000	)		0.25
Stock options exercised on March 26, 2018		(240,000	)		0.25
Stock options exercised on March 28, 2018		(325,000	)		0.25
Stock options exercised on March 29, 2018		(562,996	)		2.75
Stock options exercised on April 20, 2018		(154,000	)		0.25
Stock options expired on April 21, 2018		(1,946,000	)		0.25
Stock options cancelled on June 8, 2018		(100,000	)		1.50
Stock options cancelled on June 21, 2018		(400,000	)		1.50
Balance at June 30, 2018		3,852,004			1.73

As at

June 30, 2018,

details of the issued and outstanding stock options are as follows:

Grant date	Exercise price (CDN$)		Number of options issued and outstanding		Number of vested options outstanding		Weighted Avg Remaining Life (years)
December 21, 2016	$	1.50		2,600,000		2,600,000		0.48
February 24, 2017	$	1.50		535,000		535,000		0.65
August 14, 2017 a	$	2.75		5,000		5,000		0.25
August 14, 2017 a	$	2.75		637,004		637,004		1.12
August 14, 2017 b	$	2.75		75,000		75,000		0.12

The fair value of options granted during the

three

and

six

months ended

June 30, 2018

and year ended

December 31, 2017

was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions:

	February 24, 2017		August 14, 2017 (a)		August 14, 2017 (b)
Volatility		59%		59%		83%
Risk-free interest rate		0.81%		1.22%		1.22%
Expected life (in years)		2		2		1
Dividend yield		0%		0%		0%
Common share price		CDN $1.35		CDN $2.40		CDN $2.40
Strike price		CDN $1.50		CDN $2.75		CDN $2.75
Forfeiture rate		nil		nil		nil

The Company recorded

$1,597

of stock-based compensation for the

three

months ended

June 30, 2018 (

three

months ended

June 30, 2017 -

$Nil

). The Company recorded

$7,288

of stock-based compensation for the

six

months ended

June 30, 2018 (

six

months ended

June 30, 2017 -

$161,590

). The Company recorded the cash receipt of

$30,522

as capital stock and reclassified

$6,517

of stock-based compensation to capital stock due to the exercise of

154,000

options during the

three

months ended

June 30, 2018.

The Company recorded the cash receipt of

$1,438,308

as capital stock and reclassified

$357,954

of stock-based compensation to capital stock due to the exercise of

1,781,996

options during the

six

months ended

June 30, 2018.

Volatility is determined based on volatilities of comparable companies when the Company does

not

have its own sufficient trading history. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options.

The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is

Nil

as the Company is

not

expected to pay dividends in the foreseeable future. The Company has estimated its stock option forfeitures to be

Nil

for the

three

and

six

months ended

June 30, 2018 (

three

and

six

months ended

June 30, 2017 -

$Nil

).

XML

Note 11 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

11. Commitments and contingencies

Total future annual lease payments for the premises are as follows:

2018		8,696
Total	$	8,696

XML

Note 12 - Financial Instruments

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Financial Instruments Disclosure [Text Block]

12. Financial instruments

(a) Fair values

The Company follows ASC topic

820,

“Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC topic

820

apply to other accounting pronouncements that require or permit fair value measurements. ASC topic

820

defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a

three

level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refers broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into

three

broad levels. The

three

levels of the hierarchy are defined as follows:

Level

1

inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level

2

inputs are inputs other than quoted prices included within Level

1

that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument.

Level

3

inputs are unobservable inputs for asset or liabilities.

The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options.

An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options.

The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments.

(b) Interest rate and credit risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does

not

believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative to interest rates on cash and cash equivalents, due to related parties due to the short-term nature of these balances.

The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is

not

subject to any external restrictions.

(c) Foreign exchange risk

The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of

$1.0

 million, a +/-

10%

movement in the Canadian currency held by the Company versus the U.S. dollar would affect the Company’s loss and other comprehensive loss by

$0.1

 million.

(d) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.

The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at

June 30, 2018

and

December 31, 2017:

					June 30, 2018
	Less than 3 months	3 to 6 months	6 to 9 months	9 months 1 year	Greater than 1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	1,683,802	-	-	-	-	1,683,802
	1,683,802	-	-	-	-	1,683,802
					December 31, 2017
	Less than	3 to 6	6 to 9	9 months	Greater than
	3 months	months	months	1 year	1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	828,737	-	-	-	-	828,737
	828,737	-	-	-	-	828,737

XML

Note 13 - Segmented Information

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

13. Segmented information

The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion pet. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America (“US”).

	June 30, 2018		December 31, 2017
		$		$
Total assets
Canada		4,310,164		3,519,918
US		2,107,795		1,695,904
Total property and equipment
US		444,692		371,157

XML

Note 14 - Schedule of Expenses

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Operating Expenses [Text Block]

14. Schedule of expenses

	For the three months ended June 30, 2018						For the three months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	174,067	$	-	$	859,268	$	189,091	$	-	$	414,567
Contracted expenditures		438,689		-		-		111,450		-		-
Marketing and investor relations		-		-		41,962		-		-		63,084
Travel and accommodation		3,547		-		70,463		991		-		100,443
Insurance		28,284		-		77,282		20,206		-		42,581
License fees		1,738,513		-		-		-		-		-
Office		3,129		-		61,460		3,767		-		19,897
Consultants		52,073		336,455		-		76,005		314,658		-
Regulatory		19,388		-		90,142		25,775		-		57,681
Rent		7,825		-		43,019		12,040		-		38,805
Supplies		69,105		-		4,894		64,910		-		11,551
Total	$	2,534,620	$	336,455	$	1,248,490	$	504,235	$	314,658	$	748,610

	For the six months ended June 30, 2018						For the six months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	326,439	$	-	$	1,502,555	$	360,002	$	-	$	971,430
Contracted expenditures		708,212		-		-		359,295		-		5,610
Marketing and investor relations		-		-		123,155		-		-		103,182
Travel and accommodation		5,336		-		191,868		2,958		-		178,785
Insurance		44,244		-		157,743		37,673		-		84,101
License fees		1,738,513		-		-		-		-		-
Office		34,646		-		138,406		11,868		-		50,165
Consultants		89,189		708,402		-		168,449		696,194		-
Regulatory		38,175		-		193,700		51,550		-		72,135
Rent		15,652		-		86,038		19,264		-		82,426
Supplies		134,554		-		15,196		109,625		-		27,800
Total	$	3,134,961	$	708,402	$	2,408,662	$	1,120,684	$	696,194	$	1,575,635

XML

Note 15 - Capital Risk Management

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Capital Risk Management [Text Block]

15. Capital risk management

The capital of the Company includes equity, which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

XML

Note 16 - Loss Per Share

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

16. Loss per share

	For the three months ended June 30,						For the six months ended June 30,
	2018			2017			2018			2017
Numerator
Net loss for the period	$	4,144,398		$	1,588,370		$	6,315,727		$	3,421,106
Denominator
Weighted average shares - basic		92,527,470			87,077,768			91,527,862			85,622,780
Stock options		-			-			-			-
Denominator for diluted loss per share		92,527,470			87,077,768			91,527,862			85,622,780
Loss per share - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.07	)	$	(0.04	)

For the above mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

XML

Note 17 - Related Party Transactions and Key Management Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

17. Related party transactions and key management compensation

Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows:

	For the three months ended June 30,				For the six months ended June 30,
	2018		2017		2018		2017
Salaries and benefits, including bonuses	$	381,046	$	317,803	$	721,665	$	640,589
Stock-based compensation		-		-		-		151,020
Total	$	381,046	$	317,803	$	721,665	$	791,609

XML

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of estimates

The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.

Basis of Measurement [Policy Text Block]

Basis of measurement

The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.

Functional and Reporting Currencies [Policy Text Block]

Functional and reporting currencies

The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency.

The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.

Research and Development Expense, Policy [Policy Text Block]

Research and development

Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic

730.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Translation of foreign currencies

In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.

Compensation Related Costs, Policy [Policy Text Block]

Stock-based compensation

The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated.

The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do

not

require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest.

The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Earnings Per Share, Policy [Policy Text Block]

Loss per share

Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were

not

included in the computation of diluted EPS because the Company has incurred a loss for the

six

months ended

June 30, 2018

as the effect would be anti-dilutive.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive loss

The Company follows ASC topic

220.

This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders' equity. The Company has

no

other comprehensive loss items.

New Accounting Pronouncements, Policy [Policy Text Block]

Future accounting pronouncements

In

February 2016,

the FASB issued new guidance, ASU

No.

2016

-

02,

Leases (Topic

842

). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic

842

is effective for annual reporting periods (including interim reporting periods) beginning after

December 15, 2018.

Early adoption is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.

XML

Note 6 - Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Property, Plant and Equipment [Table Text Block]

	Computer equipment		Furniture and equipment		Laboratory equipment		Leasehold improvements		Total
Cost
Balance at December 31, 2016	$	61,598	$	7,364	$	243,529	$	25,672	$	338,163
Additions		89,557		68,694		2,200		11,285		171,736
Balance at December 31, 2017		151,155		76,058		245,729		36,957		509,899
Additions		22,763		4,172		110,758		-		137,693
Balance at June 30, 2018		173,918		80,230		356,487		36,957		647,592
Accumulated depreciation
Balance at December 31, 2016		13,858		1,490		29,783		3,998		49,129
Depreciation		28,944		10,355		45,092		5,222		89,613
Balance at December 31, 2017		42,802		11,845		74,875		9,220		138,742
Depreciation		20,284		5,754		20,558		17,562		64,158
Balance at June 30, 2018		63,086		17,599		95,433		26,782		202,900
Net book value as at:
December 31, 2017	$	108,353	$	64,213	$	170,854	$	27,737	$	371,157
June 30, 2018	$	110,832	$	62,631	$	261,054	$	10,175	$	444,692

XML

Note 7 - Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	Computer software		Trademarks		Total
Cost
Balance at December 31, 2016	$	5,143	$	16,236	$	21,379
Additions		-		-		-
Balance at December 31, 2017		5,143		16,236		21,379
Additions		-		-		-
Balance at June 30, 2018		5,143		16,236		21,379
Accumulated amortization
Balance at December 31, 2016		2,428		1,013		3,441
Amortization		1,715		1,082		2,797
Balance at December 31, 2017		4,143		2,095		6,238
Amortization		842		537		1,379
Balance at June 30, 2018		4,985		2,632		7,617
Net book value as at:
December 31, 2017	$	1,000	$	14,141	$	15,141
June 30, 2018	$	158	$	13,604	$	13,762

XML

Note 9 - Capital Stock (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

	Number of common stock		Capital stock
Balance at December 31, 2016		83,964,569	$	10,189,973
Stock issuance for services		43,613		45,000
Stock issued due to exercise of options		497,060		53,707
Stock issuance for financing, net of costs		2,902,682		3,215,876
Balance at June 30, 2017		87,407,924	$	13,504,556
Balance at December 31, 2017		90,225,869	$	18,244,659
Stock issuance for services (i)		641,717		1,238,513
Stock issued due to exercise of options (Note 10)		1,781,996		1,796,262
Stock issuance for financing, net of costs (ii)		1,861,627		3,978,690
Balance at June 30, 2018		94,511,209	$	25,258,124

XML

Note 10 - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Options			Weighted Avg Exercise Price (CDN$)
Balance at December 31, 2016		7,975,000			0.84
Stock options exercised on February 21, 2017		(10,000	)		0.25
Stock options exercised on February 21, 2017		(400,000	)		0.05
Options issued on February 24, 2017		535,000			1.50
Stock options exercised on May 8, 2017		(7,060	)		1.50
Stock options cancelled on May 17, 2017		(10,000	)		1.50
Stock options exercised on May 23, 2017		(80,000	)		0.25
Stock options exercised on July 6, 2017		(200,000	)		0.05
Stock options exercised on July 17, 2017		(220,000	)		0.25
Options issued on August 14, 2017		1,280,000			2.75
Stock options exercised on August 29, 2017		(7,940	)		1.50
Stock options exercised on December 19, 2017		(25,000	)		0.25
Stock options exercised on December 19, 2017		(750,000	)		1.50
Balance at December 31, 2017		8,080,000			1.21
Stock options exercised on January 8, 2018		(124,000	)		0.25
Stock options exercised on January 26, 2018		(100,000	)		0.25
Stock options exercised on March 8, 2018		(50,000	)		0.25
Stock options exercised on March 13, 2018		(176,000	)		0.25
Stock options exercised on March 22, 2018		(50,000	)		0.25
Stock options exercised on March 26, 2018		(240,000	)		0.25
Stock options exercised on March 28, 2018		(325,000	)		0.25
Stock options exercised on March 29, 2018		(562,996	)		2.75
Stock options exercised on April 20, 2018		(154,000	)		0.25
Stock options expired on April 21, 2018		(1,946,000	)		0.25
Stock options cancelled on June 8, 2018		(100,000	)		1.50
Stock options cancelled on June 21, 2018		(400,000	)		1.50
Balance at June 30, 2018		3,852,004			1.73

Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

Grant date	Exercise price (CDN$)		Number of options issued and outstanding		Number of vested options outstanding		Weighted Avg Remaining Life (years)
December 21, 2016	$	1.50		2,600,000		2,600,000		0.48
February 24, 2017	$	1.50		535,000		535,000		0.65
August 14, 2017 a	$	2.75		5,000		5,000		0.25
August 14, 2017 a	$	2.75		637,004		637,004		1.12
August 14, 2017 b	$	2.75		75,000		75,000		0.12

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	February 24, 2017		August 14, 2017 (a)		August 14, 2017 (b)
Volatility		59%		59%		83%
Risk-free interest rate		0.81%		1.22%		1.22%
Expected life (in years)		2		2		1
Dividend yield		0%		0%		0%
Common share price		CDN $1.35		CDN $2.40		CDN $2.40
Strike price		CDN $1.50		CDN $2.75		CDN $2.75
Forfeiture rate		nil		nil		nil

XML

Note 11 - Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

2018		8,696
Total	$	8,696

XML

Note 12 - Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]

					June 30, 2018
	Less than 3 months	3 to 6 months	6 to 9 months	9 months 1 year	Greater than 1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	1,683,802	-	-	-	-	1,683,802
	1,683,802	-	-	-	-	1,683,802
					December 31, 2017
	Less than	3 to 6	6 to 9	9 months	Greater than
	3 months	months	months	1 year	1 year	Total
	$	$	$	$	$	$
Third parties
Accounts payable and accrued liabilities	828,737	-	-	-	-	828,737
	828,737	-	-	-	-	828,737

XML

Note 13 - Segmented Information (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Long-lived Assets by Geographic Areas [Table Text Block]

	June 30, 2018		December 31, 2017
		$		$
Total assets
Canada		4,310,164		3,519,918
US		2,107,795		1,695,904
Total property and equipment
US		444,692		371,157

XML

Note 14 - Schedule of Expenses (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Operating Expenses [Table Text Block]

	For the three months ended June 30, 2018						For the three months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	174,067	$	-	$	859,268	$	189,091	$	-	$	414,567
Contracted expenditures		438,689		-		-		111,450		-		-
Marketing and investor relations		-		-		41,962		-		-		63,084
Travel and accommodation		3,547		-		70,463		991		-		100,443
Insurance		28,284		-		77,282		20,206		-		42,581
License fees		1,738,513		-		-		-		-		-
Office		3,129		-		61,460		3,767		-		19,897
Consultants		52,073		336,455		-		76,005		314,658		-
Regulatory		19,388		-		90,142		25,775		-		57,681
Rent		7,825		-		43,019		12,040		-		38,805
Supplies		69,105		-		4,894		64,910		-		11,551
Total	$	2,534,620	$	336,455	$	1,248,490	$	504,235	$	314,658	$	748,610

	For the six months ended June 30, 2018						For the six months ended June 30, 2017
	Research and Development		Professional Fees		General and Administrative		Research and Development		Professional Fees		General and Administrative
Salaries, bonus and benefits	$	326,439	$	-	$	1,502,555	$	360,002	$	-	$	971,430
Contracted expenditures		708,212		-		-		359,295		-		5,610
Marketing and investor relations		-		-		123,155		-		-		103,182
Travel and accommodation		5,336		-		191,868		2,958		-		178,785
Insurance		44,244		-		157,743		37,673		-		84,101
License fees		1,738,513		-		-		-		-		-
Office		34,646		-		138,406		11,868		-		50,165
Consultants		89,189		708,402		-		168,449		696,194		-
Regulatory		38,175		-		193,700		51,550		-		72,135
Rent		15,652		-		86,038		19,264		-		82,426
Supplies		134,554		-		15,196		109,625		-		27,800
Total	$	3,134,961	$	708,402	$	2,408,662	$	1,120,684	$	696,194	$	1,575,635

XML

Note 16 - Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	For the three months ended June 30,						For the six months ended June 30,
	2018			2017			2018			2017
Numerator
Net loss for the period	$	4,144,398		$	1,588,370		$	6,315,727		$	3,421,106
Denominator
Weighted average shares - basic		92,527,470			87,077,768			91,527,862			85,622,780
Stock options		-			-			-			-
Denominator for diluted loss per share		92,527,470			87,077,768			91,527,862			85,622,780
Loss per share - basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.07	)	$	(0.04	)

XML

Note 17 - Related Party Transactions and Key Management Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Key Management Personnel Compensation [Table Text Block]

	For the three months ended June 30,				For the six months ended June 30,
	2018		2017		2018		2017
Salaries and benefits, including bonuses	$	381,046	$	317,803	$	721,665	$	640,589
Stock-based compensation		-		-		-		151,020
Total	$	381,046	$	317,803	$	721,665	$	791,609

XML

Note 3 - Significant Accounting Policies (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Other Comprehensive Income (Loss), Net of Tax, Total	$ 0

XML

Note 5 - Prepaid Expenses and Deposits (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Aug. 26, 2016
Prepaid Rent, Current and Noncurrent			$ 801,973
Prepaid Rent	$ 155,220	$ 155,220

XML

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Cost, Beginning Balance	$ 509,899	$ 338,163
Cost, Additions	137,693	171,736
Cost, Ending Balance	647,592	509,899
Accumulated Depreciation, Beginning Balance	138,742	49,129
Accumulated Depreciation, Depreciation	64,158	89,613
Accumulated Depreciation, Ending Balance	202,900	138,742
Net Book Value	444,692	371,157
Computer Equipment [Member]
Cost, Beginning Balance	151,155	61,598
Cost, Additions	22,763	89,557
Cost, Ending Balance	173,918	151,155
Accumulated Depreciation, Beginning Balance	42,802	13,858
Accumulated Depreciation, Depreciation	20,284	28,944
Accumulated Depreciation, Ending Balance	63,086	42,802
Net Book Value	110,832	108,353
Furniture and Fixtures [Member]
Cost, Beginning Balance	76,058	7,364
Cost, Additions	4,172	68,694
Cost, Ending Balance	80,230	76,058
Accumulated Depreciation, Beginning Balance	11,845	1,490
Accumulated Depreciation, Depreciation	5,754	10,355
Accumulated Depreciation, Ending Balance	17,599	11,845
Net Book Value	62,631	64,213
Laboratory Equipment [Member]
Cost, Beginning Balance	245,729	243,529
Cost, Additions	110,758	2,200
Cost, Ending Balance	356,487	245,729
Accumulated Depreciation, Beginning Balance	74,875	29,783
Accumulated Depreciation, Depreciation	20,558	45,092
Accumulated Depreciation, Ending Balance	95,433	74,875
Net Book Value	261,054	170,854
Leasehold Improvements [Member]
Cost, Beginning Balance	36,957	25,672
Cost, Additions		11,285
Cost, Ending Balance	36,957	36,957
Accumulated Depreciation, Beginning Balance	9,220	3,998
Accumulated Depreciation, Depreciation	17,562	5,222
Accumulated Depreciation, Ending Balance	26,782	9,220
Net Book Value	$ 10,175	$ 27,737

XML

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Cost, Beginning Balance			$ 21,379	$ 21,379	$ 21,379
Cost, Additions
Cost, Ending Balance	$ 21,379		21,379		21,379
Accumulated Amortization, Beginning Balance			6,238	3,441	3,441
Accumulated Amortization, Amortization	693	$ 700	1,379	1,399	2,797
Accumulated Amortization, Ending Balance	7,617		7,617		6,238
Net Book Value	13,762		13,762		15,141
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance			5,143	5,143	5,143
Cost, Additions
Cost, Ending Balance	5,143		5,143		5,143
Accumulated Amortization, Beginning Balance			4,143	2,428	2,428
Accumulated Amortization, Amortization			842		1,715
Accumulated Amortization, Ending Balance	4,985		4,985		4,143
Net Book Value	158		158		1,000
Trademarks [Member]
Cost, Beginning Balance			16,236	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236		16,236		16,236
Accumulated Amortization, Beginning Balance			2,095	$ 1,013	1,013
Accumulated Amortization, Amortization			537		1,082
Accumulated Amortization, Ending Balance	2,632		2,632		2,095
Net Book Value	$ 13,604		$ 13,604		$ 14,141

XML

Note 8 - Loan Arrangements (Details Textual) - Loan Arrangement With Shareholder [Member] - USD ($)	Oct. 17, 2017	Jun. 30, 2018
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		$ 0

XML

Note 9 - Capital Stock (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 28, 2018	May 15, 2018	May 10, 2018	Jun. 28, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018		Jun. 30, 2017
Stock Issued During Period, Value, Issued for Services							$ 1,238,513		$ 45,000
Proceeds from Issuance of Common Stock	$ 3,452,496	$ 550,000			$ 4,002,496	$ 3,000,000	4,002,496		3,250,000
Payments of Stock Issuance Costs				$ 23,806	$ 23,806	$ 25,260	$ 23,806		$ 34,124
Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services			641,717				641,717	[1]	43,613
Stock Issued During Period, Value, Issued for Services			$ 1,238,513				$ 1,238,513	[1]	$ 45,000
Stock Issued During Period, Shares, New Issues	1,605,812	255,815					1,861,627	[2]	2,902,682

[1] On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

[2] On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

XML

Note 9 - Capital Stock - Issued and Outstanding Common Shares (Details) - USD ($)																		3 Months Ended		6 Months Ended
	Jun. 28, 2018	May 15, 2018	May 10, 2018	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Aug. 29, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 08, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018		Jun. 30, 2017
Number of common shares, beginning balance (in shares)																				90,225,869
Stock issuance for services																				$ 1,238,513		$ 45,000
Stock issued due to exercise of options (in shares)				154,000	562,996	325,000	240,000	50,000	176,000	50,000	100,000	124,000	7,940	220,000	200,000	80,000	7,060	154,000	87,060	1,781,996		497,060
Stock issued due to exercise of options																				$ 1,438,308		$ 39,544
Stock issuance for financing, net of costs																				$ 3,978,690		$ 3,215,876
Number of common shares, ending balance (in shares)																		94,511,209		94,511,209
Common Stock [Member]
Number of common shares, beginning balance (in shares)																				90,225,869		83,964,569
Capital stock, beginning balance																				$ 18,244,659		$ 10,189,973
Stock issuance for services (in shares)			641,717																	641,717	[1]	43,613
Stock issuance for services			$ 1,238,513																	$ 1,238,513	[1]	$ 45,000
Stock issued due to exercise of options (in shares)																				1,781,996		497,060
Stock issued due to exercise of options																				$ 1,796,262		$ 53,707
Stock issuance for financing, net of costs (in shares)	1,605,812	255,815																		1,861,627	[2]	2,902,682
Stock issuance for financing, net of costs																				$ 3,978,690	[2]	$ 3,215,876
Number of common shares, ending balance (in shares)																		94,511,209	87,407,924	94,511,209		87,407,924
Capital stock, ending balance																		$ 25,258,124	$ 13,504,556	$ 25,258,124		$ 13,504,556

[1] On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.

[2] On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

XML

Note 10 - Stock-based Compensation (Details Textual) - USD ($)																	3 Months Ended		6 Months Ended
	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Aug. 29, 2017	Aug. 14, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 08, 2017	Feb. 24, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	154,000	562,996	325,000	240,000	50,000	176,000	50,000	100,000	124,000	7,940		220,000	200,000	80,000	7,060		154,000	87,060	1,781,996	497,060
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											1,280,000					535,000				535,000
Allocated Share-based Compensation Expense, Total																	$ 1,597	$ 0	$ 7,288	$ 161,590
Proceeds from Stock Options Exercised																	$ 30,522	$ 22,395	1,438,308	39,544
Stock Issued During Period, Value, Stock Options Exercised																			$ 1,438,308	$ 39,544
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments																			$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate																	0.00%	0.00%	0.00%	0.00%
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised																	$ (6,517)		$ (357,954)	$ (14,163)

XML

Note 10 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares																							3 Months Ended		6 Months Ended
	Jun. 21, 2018	Jun. 08, 2018	Apr. 21, 2018	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Dec. 19, 2017	Aug. 29, 2017	Aug. 14, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 17, 2017	May 08, 2017	Feb. 24, 2017	Feb. 21, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Number of Options, Options Outstanding (in shares)																							3,852,004		3,852,004		8,080,000	7,975,000
Weighted Avg Exercise Price, Options Outstanding (in CAD per share)																							$ 1.73		$ 1.73		$ 1.21	$ 0.84
Number of Options, Options Exercised (in shares)				(154,000)	(562,996)	(325,000)	(240,000)	(50,000)	(176,000)	(50,000)	(100,000)	(124,000)		(7,940)		(220,000)	(200,000)	(80,000)		(7,060)			(154,000)	(87,060)	(1,781,996)	(497,060)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)	$ 1.50	$ 1.50	$ 0.25	$ 0.25	$ 2.75	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25		$ 1.50		$ 0.25	$ 0.05	$ 0.25		$ 1.50
Number of Options, Options Issued (in shares)															1,280,000						535,000					535,000
Weighted Avg Exercise Price, Options Issued (in CAD per share)															$ 2.75						$ 1.50
Number of Options, Options Canceled (in shares)																			(10,000)
Weighted Avg Exercise Price, Options Cancelled (in CAD per share)																			$ 1.50
Stock options expired on April 21, 2018 (in shares)			(1,946,000)
Stock options cancelled on June 8, 2018 (in shares)	(400,000)	(100,000)
Options 1 [Member]
Number of Options, Options Exercised (in shares)													(25,000)									(10,000)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)													$ 0.25									$ 0.25
Options 2 [Member]
Number of Options, Options Exercised (in shares)													(750,000)									(400,000)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)													$ 1.50									$ 0.05

XML

Note 10 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares			6 Months Ended
	Aug. 14, 2017	Feb. 24, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted Avg Exercise Price, Options Issued (in CAD per share)	$ 2.75	$ 1.50
Number of Options, Options Outstanding (in shares)			3,852,004	8,080,000	7,975,000
December 21, 2016 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			2,600,000
Number of Vested Options (in shares)			2,600,000
Weighted Avg Remaining Life (Year)			175 days
February 24, 2017 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			535,000
Number of Vested Options (in shares)			535,000
Weighted Avg Remaining Life (Year)			237 days
August 14, 2017 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 2.75
Number of Options, Options Outstanding (in shares)			5,000
Number of Vested Options (in shares)			5,000
Weighted Avg Remaining Life (Year)			91 days
August 14, 2017 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 2.75
Number of Options, Options Outstanding (in shares)			637,004
Number of Vested Options (in shares)			637,004
Weighted Avg Remaining Life (Year)			1 year 43 days
August 14, 2017 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 2.75
Number of Options, Options Outstanding (in shares)			75,000
Number of Vested Options (in shares)			75,000
Weighted Avg Remaining Life (Year)			43 days

XML

Note 10 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Aug. 14, 2017	Feb. 24, 2017
Volatility		59.00%
Risk-free interest rate		0.81%
Expected life (Year)		2 years
Dividend yield		0.00%
Common share price (in CAD per share)		$ 1.35
Strike price (in CAD per share)		$ 1.50
Forfeiture rate
Options 1 [Member]
Volatility	59.00%
Risk-free interest rate	1.22%
Expected life (Year)	2 years
Dividend yield	0.00%
Common share price (in CAD per share)	$ 2.40
Strike price (in CAD per share)	$ 2.75
Options 2 [Member]
Volatility	83.00%
Risk-free interest rate	1.22%
Expected life (Year)	1 year
Dividend yield	0.00%
Common share price (in CAD per share)	$ 2.40
Strike price (in CAD per share)	$ 2.75

XML

Note 11 - Commitments and Contingencies - Future Annual Lease Payments (Details)	Jun. 30, 2018 USD ($)
2018	$ 8,696
Total	$ 8,696

XML

Note 12 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Maturity Less Than 3 Months	$ 1,683,802	$ 828,737
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities, Maturity Greater Than 1 Year
Accounts payable and accrued liabilities	1,683,802	828,737
Contractual Financial Liabilities, Maturity Less Than 3 Months	1,683,802	828,737
Contractual Financial Liabilities, Maturity 3 to 6 Months
Contractual Financial Liabilities, Maturity 6 to 9 Months
Contractual Financial Liabilities, Maturity 9 to 12 Months
Contractual Financial Liabilities, Maturity Greater Than 1 Year
Contractual Financial Liabilities	$ 1,683,802	$ 828,737

XML

Note 13 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Assets	$ 6,417,959	$ 5,215,822
Property and equipment	444,692	371,157
CANADA
Assets	4,310,164	3,519,918
UNITED STATES
Assets	2,107,795	1,695,904
Property and equipment	$ 444,692	$ 371,157

XML

Note 14 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research and development	$ 2,534,620	$ 504,235	$ 3,134,961	$ 1,120,684
Professional fees	336,455	314,658	708,402	696,194
General and administrative	1,248,490	748,610	2,408,662	1,575,635
Salaries, Bonus and Benefits [Member]
Research and development	174,067	189,091	326,439	360,002
Professional fees
General and administrative	859,268	414,567	1,502,555	971,430
Contracted Expenditures [Member]
Research and development	438,689	111,450	708,212	359,295
Professional fees
General and administrative				5,610
Marketing and Investor Relations [Member]
Research and development
Professional fees
General and administrative	41,962	63,084	123,155	103,182
Travel and Accommodation [Member]
Research and development	3,547	991	5,336	2,958
Professional fees
General and administrative	70,463	100,443	191,868	178,785
Insurance [Member]
Research and development	28,284	20,206	44,244	37,673
Professional fees
General and administrative	77,282	42,581	157,743	84,101
License Fees [Member]
Research and development	1,738,513		1,738,513
Professional fees
General and administrative
Office [Member]
Research and development	3,129	3,767	34,646	11,868
Professional fees
General and administrative	61,460	19,897	138,406	50,165
Consultant [Member]
Research and development	52,073	76,005	89,189	168,449
Professional fees	336,455	314,658	708,402	696,194
General and administrative
Regulatory [Member]
Research and development	19,388	25,775	38,175	51,550
Professional fees
General and administrative	90,142	57,681	193,700	72,135
Rent [Member]
Research and development	7,825	12,040	15,652	19,264
Professional fees
General and administrative	43,019	38,805	86,038	82,426
Supplies [Member]
Research and development	69,105	64,910	134,554	109,625
Professional fees
General and administrative	$ 4,894	$ 11,551	$ 15,196	$ 27,800

XML

Note 16 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss for the period	$ 4,144,398	$ 1,588,370	$ 6,315,727	$ 3,421,106
Weighted average shares - basic (in shares)	92,527,470	87,077,768	91,527,862	85,622,780
Stock options (in shares)
Denominator for diluted loss per share (in shares)	92,527,470	87,077,768	91,527,862	85,622,780
Loss per share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.02)	$ (0.07)	$ (0.04)

XML

Note 17 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock-based compensation	$ 1,597	$ 0	$ 7,288	$ 161,590
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	381,046	317,803	721,665	640,589
Stock-based compensation				151,020
Total	$ 381,046	$ 317,803	$ 721,665	$ 791,609